Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Jun. 15, 2023 | Jun. 30, 2022 | |
Document Information Line Items | |||
Entity Registrant Name | MITESCO, INC. | ||
Trading Symbol | N/A | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Common Stock, Shares Outstanding | 5,115,437 | ||
Entity Public Float | $ 23,837,001 | ||
Amendment Flag | false | ||
Entity Central Index Key | 0000802257 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | Dec. 31, 2022 | ||
Document Fiscal Year Focus | 2022 | ||
Document Fiscal Period Focus | FY | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
ICFR Auditor Attestation Flag | true | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Entity File Number | 000-53601 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Tax Identification Number | 87-0496850 | ||
Entity Address, Address Line One | 18202 Minnetonka Blvd., Suite 100 | ||
Entity Address, City or Town | Deephaven | ||
Entity Address, State or Province | MN | ||
Entity Address, Postal Zip Code | 55391 | ||
City Area Code | 844 | ||
Local Phone Number | 383-8689 | ||
Title of 12(b) Security | N/A | ||
Security Exchange Name | NONE | ||
Entity Interactive Data Current | Yes | ||
Document Financial Statement Error Correction [Flag] | false | ||
Auditor Firm ID | 587 | ||
Auditor Name | RBSM LLP | ||
Auditor Location | Las Vegas, NV |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash and cash equivalents | $ 35,623 | $ 1,164,483 |
Accounts Receivable | 30,943 | 44,313 |
Inventory | 0 | 25,314 |
Prepaid expenses | 113,722 | 72,985 |
Total current assets | 180,288 | 1,307,095 |
Right to use operating leases, net | 544,063 | 3,886,866 |
Construction in progress | 0 | 1,984,701 |
Fixed assets, net of accumulated depreciation of $.06 million and $19,600 | 1,877,629 | 3,476,164 |
Total Assets | 2,601,980 | 10,654,826 |
Current liabilities | ||
Accounts payable and accrued liabilities | 7,353,215 | 3,976,064 |
Accrued interest | 362,094 | 7,657 |
Derivative liabilities | 568,912 | 0 |
Lease liability - operating leases, current | 442,866 | 161,838 |
Notes payable, net of discounts | 5,112,701 | 0 |
SBA Loan Payable | 460,406 | 460,406 |
Other current liabilities | 96,136 | 169,422 |
Preferred stock dividends payable | 395,407 | 145,539 |
Total current liabilities | 17,802,471 | 5,558,988 |
Lease Liability- operating leases, non-current | 3,936,858 | 3,972,964 |
Total Liabilities | 21,739,329 | 9,531,952 |
Commitments and contingencies | ||
Preferred stock, Value | 0 | 0 |
Common stock subscribed | 36,575 | 132,163 |
Common stock, $0.01 par value, 500,000,000 shares authorized, 4,630,372 and 4,266,669 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 46,305 | 42,667 |
Additional paid-in capital | 29,452,514 | 26,385,728 |
Accumulated deficit | (48,714,461) | (25,478,332) |
Total stockholders' equity (deficit) | (19,137,349) | 1,122,874 |
Total liabilities and stockholders' equity (deficit) | 2,601,980 | 10,654,826 |
Series A Preferred Stock [Member] | ||
Current liabilities | ||
Preferred stock, Value | 0 | 0 |
Series C Preferred Stock [Member] | ||
Current liabilities | ||
Preferred stock, Value | 10,476 | 9,406 |
Series D Preferred Stock [Member] | ||
Current liabilities | ||
Preferred stock, Value | 31,000 | 31,000 |
Series X Preferred Stock [Member] | ||
Current liabilities | ||
Preferred stock, Value | 242 | 242 |
Related Party [Member] | ||
Current liabilities | ||
Accrued interest | 198,753 | 0 |
Notes payable, net of discounts | 2,776,962 | 588,432 |
Preferred stock dividends payable | $ 35,019 | $ 49,630 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Fixed assets, accumulated depreciation (in Dollars) | $ 60,000 | $ 19,600 |
Notes payable, discounts (in Dollars) | $ 40,000 | $ 0 |
Common stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 500,000,000 | 500,000,000 |
Common stock, shares issued | 4,630,372 | 4,266,669 |
Common stock, shares outstanding | 4,630,372 | 4,266,669 |
Series A Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Series C Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares issued | 1,038,708 | 940,644 |
Preferred stock, shares outstanding | 1,038,708 | 940,644 |
Series D Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares issued | 3,100,000 | 3,100,000 |
Preferred stock, shares outstanding | 3,100,000 | 3,100,000 |
Series X Preferred Stock [Member] | ||
Preferred stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares issued | 24,227 | 24,227 |
Preferred stock, shares outstanding | 24,227 | 24,227 |
Related Party [Member] | ||
Notes payable, discounts (in Dollars) | $ 30,000 | $ 0 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue | $ 690,534 | $ 115,994 |
Cost of goods sold | 2,056,218 | 455,587 |
Gross (loss) profit | (1,365,684) | (339,593) |
Operating expenses: | ||
General and administrative | 9,221,670 | 6,058,996 |
Impairment of fixed assets | 7,597,558 | 0 |
Total operating expenses | 16,819,228 | 6,058,996 |
Net Operating Loss | (18,184,912) | (6,398,589) |
Other income (expense): | ||
Interest expense | (3,210,763) | (968,471) |
Loss on legal settlement | 0 | (70,000) |
Loss on true-up shares | (9,007) | 0 |
Gain on waiver and commitment fee shares | 91,444 | 0 |
Gain on settlement of accrued salary | 15,032 | 0 |
(Loss) Gain on settlement of accounts payable | (88,235) | 6,045 |
Gain on settlement of notes payable | 0 | 1,836 |
Loss on revaluation of derivative liabilities | (687,178) | (493,455) |
Total other expense | (5,051,217) | (1,524,045) |
Loss before provision for income taxes | (23,236,129) | (7,922,634) |
Provision for income taxes | 0 | 0 |
Net loss | (23,236,129) | (7,922,634) |
Preferred stock dividends | (249,868) | (185,202) |
Preferred stock deemed dividends | 0 | (3,118,530) |
Net loss available to common shareholders | $ (23,558,439) | $ (11,226,366) |
Net loss per share - basic and diluted (in Dollars per share) | $ (5.29) | $ (2.77) |
Weighted average shares outstanding - basic and diluted (in Shares) | 4,451,962 | 4,060,005 |
Service [Member] | ||
Revenue | $ 673,385 | $ 115,994 |
Cost of goods sold | 1,979,688 | 455,587 |
Product [Member] | ||
Revenue | 17,149 | 0 |
Cost of goods sold | 76,530 | 0 |
Related Party [Member] | ||
Other income (expense): | ||
Interest expense | (1,243,639) | 0 |
Gain on waiver and commitment fee shares | 81,129 | 0 |
Preferred stock dividends | $ (72,442) | $ 0 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) | Diamond Note 1 [Member] Additional Paid-in Capital [Member] | Diamond Note 1 [Member] | Discount on Note Payable Due to Warrants [Member] Additional Paid-in Capital [Member] | Discount on Note Payable Due to Warrants [Member] | Convertible Debt [Member] Common Stock [Member] | Convertible Debt [Member] Additional Paid-in Capital [Member] | Convertible Debt [Member] | Accounts Payable [Member] Common Stock [Member] | Accounts Payable [Member] Additional Paid-in Capital [Member] | Accounts Payable [Member] | Series A Preferred Stock [Member] Preferred Stock [Member] | Series A Preferred Stock [Member] Common Stock [Member] | Series A Preferred Stock [Member] Additional Paid-in Capital [Member] | Series A Preferred Stock [Member] Retained Earnings [Member] | Series A Preferred Stock [Member] | Series X Preferred Stock [Member] Preferred Stock [Member] Share Settlement [Member] | Series X Preferred Stock [Member] Preferred Stock [Member] | Series X Preferred Stock [Member] Common Stock [Member] Stock Issued for Dividends Payable [Member] | Series X Preferred Stock [Member] Additional Paid-in Capital [Member] Stock Issued for Dividends Payable [Member] | Series X Preferred Stock [Member] Stock Issued for Dividends Payable [Member] | Series X Preferred Stock [Member] | Series C Preferred Stock [Member] Preferred Stock [Member] | Series C Preferred Stock [Member] Common Stock [Member] | Series C Preferred Stock [Member] Additional Paid-in Capital [Member] | Series C Preferred Stock [Member] Retained Earnings [Member] | Series C Preferred Stock [Member] | Series D Preferred Stock [Member] Preferred Stock [Member] | Series D Preferred Stock [Member] Additional Paid-in Capital [Member] | Series D Preferred Stock [Member] Retained Earnings [Member] | Series D Preferred Stock [Member] | Common Stock [Member] Private Placement [Member] | Common Stock [Member] Share-Based Payment Arrangement, Option [Member] | Common Stock [Member] Share Settlement [Member] | Common Stock [Member] Stock Subscribed [Member] | Common Stock [Member] Commitments [Member] | Common Stock [Member] Waiver Fee [Member] | Common Stock [Member] Shares Previously Subscribed [Member] | Common Stock [Member] Make-Good Agreement [Member] | Common Stock [Member] Rounding in Reverse Split [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] Private Placement [Member] | Additional Paid-in Capital [Member] Share-Based Payment Arrangement, Option [Member] | Additional Paid-in Capital [Member] Share Settlement [Member] | Additional Paid-in Capital [Member] Stock Subscribed [Member] | Additional Paid-in Capital [Member] Commitments [Member] | Additional Paid-in Capital [Member] Waiver Fee [Member] | Additional Paid-in Capital [Member] Shares Previously Subscribed [Member] | Additional Paid-in Capital [Member] Make-Good Agreement [Member] | Additional Paid-in Capital [Member] Rounding in Reverse Split [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Stock Subscribed [Member] Stock Subscribed [Member] | Stock Subscribed [Member] Shares Previously Subscribed [Member] | Stock Subscribed [Member] | Private Placement [Member] | Share-Based Payment Arrangement, Option [Member] | Share Settlement [Member] | Commitments [Member] | Waiver Fee [Member] | Make-Good Agreement [Member] | Total |
Balance at Dec. 31, 2020 | $ 48 | $ 262 | $ 31,076 | $ 11,863,557 | $ (14,437,168) | $ (2,542,225) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in Shares) at Dec. 31, 2020 | 4,800 | 26,227 | 3,107,624 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of shares issued to employees | 13,032 | 13,032 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of stock options issued to employees | 676,423 | 676,423 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 221 | 222,259 | 222,480 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in Shares) | 21,988 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued for conversion | $ 6,789 | $ 2,647,006 | $ 2,653,795 | $ (48) | $ 120 | $ (72) | $ (20) | $ (20,594) | $ 1,647 | $ 18,947 | $ 1,656 | $ (272) | $ 96 | $ 237,344 | $ 128,202 | $ 119,770 | $ (119,866) | $ 252,029 | $ 239,000 | $ 127,910 | 252,029 | ||||||||||||||||||||||||||||||||||||||||
Stock issued for conversion (in Shares) | 678,884 | (4,800) | 12,000 | (2,000) | (2,059,356) | 164,750 | 165,634 | (27,241) | 9,590 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Deemed dividend on Preferred Stock | $ 206,242 | $ (206,242) | 126,000 | $ (126,000) | $ 2,786,288 | $ (2,786,288) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred stock dividends | $ (61,818) | $ (87,059) | $ (35,327) | $ (185,204) | $ (185,204) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of Stock | $ 30,000 | $ 1,461,283 | $ 1,491,283 | $ 31,000 | $ 1,722,282 | $ 1,753,282 | $ 1,334 | $ 1,666,666 | $ 1,668,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of Stock (in Shares) | 3,000,000 | 3,100,000 | 133,440 | 4,266,669 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued (in Shares) | 1,268,717 | 1,268,717 | 1,145,418 | 1,145,418 | 261,568 | 261,568 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of accrued payroll | $ 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss for the period | (7,922,634) | (7,922,634) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2021 | $ 242 | $ 9,406 | $ 31,000 | $ 42,667 | $ 26,385,728 | (25,478,332) | 132,163 | $ 1,122,874 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in Shares) at Dec. 31, 2021 | 24,227 | 940,644 | 3,100,000 | 4,266,669 | 4,266,669 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of shares issued to employees | 4,387 | $ 4,387 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting of stock options issued to employees | 345,578 | 345,578 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 63 | 101,187 | 101,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in Shares) | 6,329 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued for conversion | $ 636 | $ 577,599 | $ 578,235 | $ 82 | $ 86,971 | $ 87,053 | $ 1,070 | $ (1,070) | $ 76 | $ 913 | $ 29 | $ 271 | $ 95,512 | $ 318,735 | $ (29) | 180,302 | $ (95,588) | $ 319,648 | 180,573 | ||||||||||||||||||||||||||||||||||||||||||
Stock issued for conversion (in Shares) | 63,593 | 8,103 | 106,975 | 7,648 | 91,329 | 2,875 | 27,064 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares | $ 1,196 | $ 452 | $ 1,218,466 | $ 366,706 | $ 1,219,662 | $ 367,158 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares (in Shares) | 119,527 | 45,235 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred stock dividends | $ (1,000) | $ (60,564) | $ (66,447) | $ (195,299) | $ (322,310) | $ (322,310) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of Stock (in Shares) | 4,630,372 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants issued (in Shares) | 2,914 | 2,914 | 2,213 | 2,213 | 89,545 | 89,545 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of accrued payroll | $ (80) | $ 80 | $ (88,235) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain on settlement of accrued payroll (in Shares) | (8,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss for the period | (23,236,129) | (23,236,129) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2022 | $ 242 | $ 10,476 | $ 31,000 | $ 46,305 | $ 29,452,514 | $ (48,714,461) | $ 36,575 | $ (19,137,349) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in Shares) at Dec. 31, 2022 | 24,227 | 1,047,619 | 3,100,000 | 4,630,372 | 4,630,372 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (Parentheticals) | 12 Months Ended |
Dec. 31, 2021 $ / shares | |
Statement of Stockholders' Equity [Abstract] | |
Preferred stock dividends, per share | $ 3.62 |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net loss | $ (23,236,129) | $ (7,922,634) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Impairment of assets | 7,597,558 | 0 |
Depreciation | 868,508 | 182,426 |
Amortization of right-to-use asset | 357,700 | 162,276 |
Net gain on settlement of notes payable | 0 | 0 |
Financing cost - waiver fee shares | 565,431 | 0 |
Gain on waiver fee shares | (198,273) | 0 |
Loss on commitment shares | 34,707 | 0 |
Gain on conversion of accrued salary | (15,032) | 0 |
(Gain) loss on revaluation of derivative liabilities | 687,178 | 493,455 |
Loss on settlement of accounts payable | 88,235 | 0 |
Amortization of discount on notes payable | 2,116,194 | 756,795 |
Share-based compensation | 451,215 | 1,039,843 |
Changes in assets and liabilities: | ||
Accounts receivables | 13,370 | (44,313) |
Prepaid expenses | 139,836 | (47,985) |
Inventory | 25,314 | (25,314) |
Accounts payable and accrued liabilities | 3,933,770 | 54,527 |
Operating lease liability, net | (126,566) | 75,017 |
Other current liabilities | (73,286) | 74,166 |
Accrued interest | 354,437 | 205,795 |
Net cash used in operating activities | (5,173,840) | (4,995,946) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Cash paid for acquisition of fixed assets and construction in progress | (1,748,826) | (1,928,192) |
Net cash used in investing activities | (1,748,826) | (1,928,192) |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from private placement of common stock | 0 | 1,668,000 |
Proceeds from sale of common stock | 0 | 51,500 |
Proceeds from landlord financing of leasehold improvements | 171,000,000,000 | |
Proceeds from convertible notes payable, net of discount | 0 | 850,000 |
Proceeds from notes payable, net of discounts | 4,359,350 | 0 |
Principal payments on notes payable | 0 | (179,368) |
Net cash provided by financing activities | 5,793,806 | 8,023,832 |
Net increase in cash and cash equivalents | (1,128,860) | 1,099,694 |
Cash and cash equivalents at beginning of period | 1,164,483 | 64,789 |
Cash and cash equivalents at end of period | 35,623 | 1,164,483 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
Interest paid | 0 | 2,680 |
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
Stock issued for common stock subscribed | 95,512 | 0 |
Settlement of derivative liabilities | 0 | (1,301,137) |
Preferred stock dividend | 322,310 | 0 |
Deemed dividends on Preferred Stock | 0 | 3,118,530 |
Conversion of payable to common stock | 0 | 50,000 |
Conversion of accounts payable to common stock subscribed | 0 | 252,029 |
Discount on notes payable due to warrants | 94,672 | 261,568 |
(Decrease) Increase in capital expenditures included in accounts payable | (51,587) | 3,291,735 |
Series C Preferred Stock [Member] | ||
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from sales of Preferred Stock, net of fees | 0 | 2,760,000 |
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
Conversion of Preferred stock to common stock | 0 | 61,781 |
Series D Preferred Stock [Member] | ||
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from sales of Preferred Stock, net of fees | 0 | 2,873,700 |
Series A Preferred Stock [Member] | ||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
Conversion of Preferred stock to common stock | 0 | 6,000 |
Accounts Payable [Member] | ||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
Conversion of payable to common stock | 578,235 | 102,333 |
Related Party [Member] | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Amortization of discount on notes payable | 1,043,240 | 0 |
Changes in assets and liabilities: | ||
Accrued interest | 198,753 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Proceeds from notes payable, net of discounts | 1,498,750 | 0 |
Principal payments on notes payable related parties | $ (235,294) | $ 0 |
Description of Business
Description of Business | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1: Description of Business Company Overview Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. Since 2020, our operations have focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. In March of 2020, we formed an owned subsidiary, Mitesco NA LLC, which holds The Good Clinic LLC, a Colorado limited liability company for our clinic business. The Company had previously established a strategy to address opportunities in Europe seeking technology solutions, or financing situations, through a Dublin based subsidiary, Acelerar Healthcare Holdings Ltd. After a review of its near-term opportunities in North America, the Board of Directors has determined that any efforts in the European community should be discontinued so that it can best focus on its North American operations. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022 we made the strategic decision to reduce our capital needs by closing our clinic operations and releasing a significant portion of our staff. As we redevelop our new strategy for lower cost operations, we hope to slowly open clinics, using the same staffing approach, but with a wider range of services for a broader portion of the population with healthcare needs. Reverse Stock Split On December 12, 2022, the Company effected a one-for-fifty (1-for-50) reverse stock split of its common stock (the “Reverse Stock Split”). All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. |
Going Concern
Going Concern | 12 Months Ended |
Dec. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Substantial Doubt about Going Concern [Text Block] | Note 2: Going Concern Effective December 8, 2022, we closed all of our clinic locations due to a lack of funding. Subsequent to that date we have lost possession of all except one clinic location. Due to difficulty in securing financing, we are uncertain of when or even if we will be able to resume operations at any clinic location. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions. The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | Note 3: Summary of Significant Accounting Policies Basis of Accounting Principles of Consolidation Use of Estimates - Cash - Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease Construction in Progress - Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition. Convertible Instruments Derivative Financial Instruments Common Stock Purchase Warrants- Stockholders Equity- Per Share Data- Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. Impairment of Long-Lived Assets- Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3. Recent Accounting Standards In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock, and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2022, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The adoption of this new guidance did not have a material effect on our consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows. |
Net Loss Per Share Applicable t
Net Loss Per Share Applicable to Common Shareholders | 12 Months Ended |
Dec. 31, 2022 | |
Earnings Per Share [Abstract] | |
Earnings Per Share [Text Block] | Note 4: Net Loss Per Share Applicable to Common Shareholders Net Loss per Share Applicable to Common Stockholders Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table sets forth the computation of loss per share for the years ended December 31, 2022 and 2021, respectively: For the Years Ended December 31, 2022 2021 Numerator: Net loss applicable to common shareholders $ (23,558,439 ) $ (11,226,366 ) Denominator: Weighted average common shares outstanding 4,451,962 4,060,005 Net loss per share: Basic and diluted $ (5.29 ) $ (2.77 ) The Company excluded all common equivalent shares for warrants, options, and convertible instruments from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2022 and 2021, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2022 2021 Options 310,692 374,924 Warrants 672,334 596,400 Preferred Stock 347,652 347,652 Accrued Interest 42,002 17,443 Total 1,372,680 1,336,419 |
Related Party Transactions
Related Party Transactions | 12 Months Ended |
Dec. 31, 2022 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | Note 5: Related Party Transactions The Company was involved in a significant number of fundraising transactions with related parties during the years ended December 31, 2022 and 2021. See notes 10 and 12. |
Accounts Payable and Accrued Li
Accounts Payable and Accrued Liabilities | 12 Months Ended |
Dec. 31, 2022 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 6: Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following at December 31, 2022 and 2021: December 31, December 31, 2022 2021 Trade accounts payable $ 6,761,793 $ 3,933,305 Accrued payroll and payroll taxes 590,915 23,554 Other 507 19,205 Total accounts payable and accrued liabilities $ 7,353,215 $ 3,976,064 Accounts Payable Exchanged for Common Stock On January 5, 2022, we entered into an exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) (the “Gardner Agreement”). Pursuant to the Gardner Agreement, we have authorized the issuance of shares of the Company’s restricted common stock to Gardner in exchange for the certain accounts payable and additional amounts due to Gardner as defined below. The Gardner Agreement settles certain amounts owed by us to Gardner (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Gardner Agreement and April 1, 2022. The Gardner Agreement also settled incurred interest and penalties on the amounts owed through January 5, 2022, as well as future interest payments on amounts to be incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount is $500,000, the Additional Costs is $294,913 and the conversion price is $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. Our Board of Directors approved the Gardner Agreement on January 5, 2022. |
Right to Use Assets and Lease L
Right to Use Assets and Lease Liabilities - Operating Leases | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Text Block [Abstract] | |
Lessee, Operating Leases [Text Block] | Note 7: Right to Use Assets and Lease Liabilities Operating Leases The Company has an operating lease for its clinic with a remaining lease term of approximately 7.5 years. The Company’s lease expense was entirely comprised of operating leases. Lease expense for the years ended December 31, 2022 and 2021 amounted to $860,705 and $351,854, respectively. The Company’s RTU asset amortization for the years ended December 31, 2022 and 2021 was $357,700 and $162,276, respectively. During the year ended December 31, 2022, the Company recognized an impairment of RTU assets in the amount of $3,185,591 in connection with the closing of its clinics during the period. The remaining difference between the lease expense and the associated RTU asset amortization consists of interest at a rate of 12% for the years ended December 31, 2022 and 2021. The weighted-average lease term outstanding was 84.0 and 92.1 months at December 31, 2022 and 2021, respectively. Right to use assets – operating leases are summarized below: December 31, 2022 December 31, 2021 Right to use assets, net $ 544,063 $ 3,886,866 Operating lease liabilities are summarized below: December 31, 2022 December 31, 2021 Lease liability $ 4,379,724 $ 4,134,802 Less: current portion (442,866 ) (161,838 ) Lease liability, non-current $ 3,936,858 $ 3,972,964 Maturity analysis under these lease agreements are as follows: For the period ended December 31, 2023 $ 945,102 For the period ended December 31, 2024 884,990 For the period ended December 31, 2025 906,666 For the period ended December 31, 2026 926,988 For the period ended December 31, 2027 946,745 Thereafter 1,939,476 Total $ 6,549,967 Less: Present value discount (2,170,243 ) Lease liability $ 4,379,724 |
SBA Loan Payable
SBA Loan Payable | 12 Months Ended |
Dec. 31, 2022 | |
Small Business Administration Loan Payable Abstract | |
Small Business Administration Loan Payable [Text Block] | Note 8: SBA Loan Payable PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note (the “Note”) with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year. During the year ended December 31, 2022, the Company accrued interest in the amount of $4,632. The current balance is $460,406. The PPP Loan is in default at December 31, 2022. |
Notes Payable
Notes Payable | 12 Months Ended |
Dec. 31, 2022 | |
Notes Payable [Line Items] | |
Debt Disclosure [Text Block] | Note 9: Notes Payable AJB Note On March 18, 2022, the Company entered into a Securities Purchase Agreement (the “AJB Agreement”) with AJB Capital Investments, LLC (“AJB”) with respect to the sale and issuance to AJB of: (i) an initial commitment fee in the amount of $430,000 in the form of 34,400 shares (the “AJB Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $750,000 (the “AJB Note”), and (iii) Common Stock Purchase Warrants to purchase 15,000 shares of the Company’s Common Stock (the “AJB Warrants”). The AJB Note and AJB Warrants were issued on March 17, 2022 and were held in escrow pending effectiveness of the AJB Agreement. Should AJB receive net proceeds of less than $430,000 from the sale of the AJB Commitment Fee Shares, the Company will issue additional shares to AJB or pay the shortfall amount to AJB in cash (the “AJB True-up Obligation”. The terms of the AJB Agreement resulted in the Company recording a derivative liability in the initial amount of $106,608. On November 18, 2022, the Company issued 91,328 shares of common stock to AJB and recorded a loss in the amount of $9,007 in connection with the settlement of the AJB True-up Obligation. See notes 11 and 12. The AJB Note was issued in the principal amount of $750,000 for a purchase price of $675,000, resulting in an original issue discount of $75,000, and has a due date, as extended, of March 17, 2023. The AJB Note bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the AJB Note this rate will increase to 18% and the AJB Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The AJB Note entered default status on October 6, 2022. The AJB Commitment Fee Shares and AJB Warrants resulted in a discount to the AJB Note in the amount of $349,914. The Company charged the amount of $62,000 to interest on the AJB Note during the year ended December 31, 2022. Discounts in the amount of $424,914 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $750,000 and $22,833, respectively, were due on the AJB Note at December 31, 2022. The AJB Note was in default at December 31, 2022. Anson Investments Note On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson Investments Agreement”) with Anson Investments Master Fund LP (“Anson Investments”) with respect to the sale and issuance to Anson Investments of: (i) an initial commitment fee in the amount of $322,500 in the form of 25,800 shares (the “Anson Investments Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $562,500 (the “Anson Investments Note”), and (iii) Common Stock Purchase Warrants to purchase 11,250 shares of the Common Stock (the “Anson Investments Warrants”). Should Anson Investments receive net proceeds of less than $322,500 from the sale of the Anson Investments Commitment Fee Shares, the Company will issue additional shares to Anson Investments or pay the shortfall amount to Anson Investments in cash. The terms of the Anson Investments Agreement resulted in the Company recording a derivative liability in the initial amount of $27,040. The Anson Investments Note was issued in the principal amount of $562,500 for a purchase price of $506,250 resulting in an original issue discount of $56,250. The Anson Investments Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson Investments Note this rate will increase to 18% and the Anson Investment Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson Investments Note entered default status on October 6, 2022. The Anson Investments Commitment Fee Shares and Anson Investments Warrants resulted in a discount to the Anson Investments Note in the amount of $416,375. The Company charged the amount of $68,844 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $472,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $562,500 and $41,500, respectively, were due on the AJB Note at December 31, 2022. The Anson Investments Note was in default at December 31, 2022. Anson East Note On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson East Agreement”) with Anson East Master Fund LP (“Anson East”) with respect to the sale and issuance to Anson East of: (i) an initial commitment fee in the amount of $107,500 in the form of 8,600 shares (the “Anson East Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $187,500 (the “Anson East Note”), and (iii) Common Stock Purchase Warrants to purchase 3,750 shares of the Company’s common stock (the “Anson East Warrants”). Should Anson East receive net proceeds of less than $107,500 from the sale of the Anson East Commitment Fee Shares, the Company will issue additional shares to Anson East or pay the shortfall amount to Anson East in cash. The terms of the Anson East Agreement resulted in the Company recording a derivative liability in the initial amount of $9,014. The Anson East Note was issued in the principal amount of $187,500 for a purchase price of $168,750 resulting in an original issue discount of $18,750. The Anson East Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson East Note this rate will increase to 18%, and the Anson East Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson East Note entered default status on October 6, 2022. The Anson East Commitment Fee Shares and Anson East Warrants resulted in a discount to the Anson East Note in the amount of $147,290. The Company charged the amount of $22,948 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $166,040 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $187,500 and $13,833, respectively, were due on the Anson East Note at December 31, 2022. The Anson East Note was in default at December 31, 2022. GS Capital Note On April 18, 2022, the Company entered into a Securities Purchase Agreement (the “GS Capital Agreement”) with GS Capital Investments, LLC (“GS Capital”) with respect to the sale and issuance to GS Capital of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “GS Capital Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “GS Capital Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “GS Capital Warrants”). Should GS Capital receive net proceeds of less than $159,259 from the sale of the GS Capital Commitment Fee Shares, the Company will issue additional shares to GS Capital or pay the shortfall amount to GS Capital in cash. The terms of the GS Capital Agreement resulted in the Company recording a derivative liability in the initial amount of $21,920. The GS Capital Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The GS Capital Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the GS Capital Note this rate will increase to 18%, and the GS Capital Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The GS Capital Note entered default status on October 19, 2022. The GS Capital Commitment Fee Shares and GS Capital Warrants resulted in a discount to the GS Capital Note in the amount of $162,158. The Company charged the amount of $32,155 to interest on the GS Capital Note during the year ended December 31, 2022. Discounts in the amount of $212,435 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $19,578, respectively, were due on the GS Capital Note at December 31, 2022. The GS Capital Note was in default at December 31, 2022. Kishon Note On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793. The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492. The Company charged the amount of $28,624 to interest on the Kishon Note during the year ended December 31, 2022. Discounts in the amount of $181,269 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $17,822, respectively, were due on the Kishon Note at December 31, 2022. The Kishon Note was in default at December 31, 2022. Finnegan Note 1 On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1. Interest in the amount of $3,285 was accrued on the Finnegan Note 1 during the year ended December 31, 2022. Discounts in the amount of $17,005 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,285, respectively, were due on the Finnegan Note 1 at December 31, 2022. The Finnegan Note 1 was in default at December 31, 2022. M Diamond Note On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note. Interest in the amount of $3,929 was accrued on the M Diamond Note during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the M Diamond Note at December 31, 2022. The M Diamond Note was in default at December 31, 2022. Finnegan Note 2 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2. Interest in the amount of $1,965 was accrued on the Finnegan Note 2 during the year ended December 31, 2022. Discounts in the amount of $10,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,965, respectively, were due on the Finnegan Note 2 at December 31, 2022. The Finnegan Note 2 was in default at December 31, 2022. Dragon Note On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $588,235 (the “Dragon Note”) to Dragon Dynamic Funds Platform Ltd (“Dragon Dynamic”). The Dragon Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 9, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dragon Note was $500,000; the amount payable at maturity will be $588,235 plus 10% of that amount plus any accrued and unpaid interest. Costs in the amount of $47,500 were charged to discount on the Dragon Note. Following an event of default as defined in the Dragon Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dragon Note entered default status on December 10, 2022, and the interest rate increased to 18%. The Dragon Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Dragon Dynamic reasonably believes contains a term that is more favorable than those in the Dragon Note, the Company shall notify Dragon Dynamic of such term, and such term, at the option of Dragon Dynamic, shall become a part of the Dragon Note. In addition, Dragon Dynamic received five-year warrants to purchase 4,824 shares of common stock at a price of $25.00 per share with a fair value of $21,500 at the date of issuance, and 4,824 shares of common stock with a value of $44,000; these amounts were recorded as discounts to the Dragon Note. Interest in the amount of $35,874 was accrued on the Dragon Note during the year ended December 31, 2022. Discounts in the amount of $260,059 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $647,059 and $35,874, respectively, were due on the Dragon Note at December 31, 2022. The Dragon Note was in default at December 31, 2022. Mackay Note On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $294,118 to Mackay Investments, LLC (the “Mackay Note”). The Mackay Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) August 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mackay Note was $250,000; the amount payable at maturity will be $294,118 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mackay Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mackay Note entered default status on August 11, 2022, and the interest rate increased to 18%. The Mackay Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mackay Investments, LLC reasonably believes contains a term that is more favorable than those in the Mackay Note, the Company shall notify Mackay Investments, LLC of such term, and such term, at the option of Mackay Investments, LLC , shall become a part of the Mackay Note. In addition, Mackay Investments, LLC received five-year warrants to purchase 2,412 shares of common stock at a price of $25.00 per share with a fair value of $10,250 at the date of issuance, and 2,412 shares of common stock with a value of $44,118; these amounts were recorded as discounts to the Mackay Note. Interest in the amount of $20,193 was accrued on the Mackay Note during the year ended December 31, 2022. Discounts in the amount of $96,280 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $323,530 and $20,193, respectively, were due on the Mackay Note at December 31, 2022. The Mackay Note was in default at December 31, 2022. Schrier Note On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note. Interest in the amount of $1,141 was accrued on the Schrier Note during the year ended December 31, 2022. Discounts in the amount of $7,367 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $335 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $25,882 and $1,141, respectively, were due on the Schrier Note at December 31, 2022. Nommsen Note On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note. Interest in the amount of $2,946 was accrued on the Nommsen Note during the year ended December 31, 2022. Discounts in the amount of $18,905 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,946, respectively, were due on the Nommsen Note at December 31, 2022. The Nommsen Note was in default at December 31, 2022. Caplan Note On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note. Interest in the amount of $2,531 was accrued on the Caplan Note during the year ended December 31, 2022. Discounts in the amount of $16,675 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $2,230 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,531, respectively, were due on the Caplan Note at December 31, 2022. Finnegan Note 3 On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3. Interest in the amount of $1,200 was accrued on the Finnegan Note 3 during the year ended December 31, 2022. Discounts in the amount of $7,575 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,728 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,200, respectively, were due on the Finnegan Note 3 at December 31, 2022. Enright Note On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $120,000 to Jack Enright (the “Enright Note”). The Enright Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Enright Note was $102,000; the amount payable at maturity will be $120,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Enright Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Enright Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Enright reasonably believes contains a term that is more favorable than those in the Enright Note, the Company shall notify Mr. Enright of such term, and such term, at the option of Mr. Enright, shall become a part of the Enright Note. In addition, Mr. Enright received 984 shares of common stock with a value of $6,317; this amount was recorded as a discount to the Enright Note. Interest in the amount of $4,899 was accrued on the Enright Note during the year ended December 31, 2022. Discounts in the amount of $29,571 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $6,746 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $132,000 and $4,899, respectively, were due on the Enright Note at December 31, 2022. Mitchell Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note ent |
Related Party [Member] | |
Notes Payable [Line Items] | |
Debt Disclosure [Text Block] | Note 10: Notes Payable Related Parties Howe Note 1 On December 30, 2021, we issued a 10% Promissory Note in the principal amount of $1,000,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 1”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 1 bears interest at the rate of 10% interest rate per annum and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 1 was $850,000; the amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Howe Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 1 entered delinquent status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security, which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 1, we shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of th e Howe Note 1. In addition, Mr. Howe five-year warrants to purchase 42,000 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 42,000 shares of common stock at $37.50 per share with an aggregate fair value of $261,568 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $106,795 was accrued on the Howe Note 1 during the year ended December 31, 2022. Discounts in the amount of $511,568 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $1,100,000 and $106,795, respectively, were due on the Howe Note 1 at December 31, 2022. The Howe Note 1 was in default at December 31, 2022. Diamond Note 1 On February 24, 2022, the Company issued a 10% Promissory Note in the principal amount of $175,000 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 1”). The Diamond Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 1 was $148,750; the amount payable at maturity will be $175,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 1, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 7,350 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 7,350 shares of common stock at $37.50 per share with an aggregate fair value of $2,914 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $16,052 was accrued on the Diamond Note 1 during the year ended December 31, 2022. Discounts in the amount of $46,664 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $192,500 and $16,052, respectively, were due on the Diamond Note 1 at December 31, 2022. The Diamond Note 1 was in default at December 31, 2022. Diamond Note 2 On March 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $235,294 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 2). The Diamond Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 2 was $200,000; the amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 2, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 1,930 shares of common stock at a price of $25.00 per share a fair value of $2,213 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $1,676 was accrued on the Diamond Note 2 during the year ended December 31, 2022. Principal in the amount of $235,294 was paid on the Diamond Note 2 during the year ended December 31, 2022. Discounts in the amount of $61,036 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $23,529 and $1,676, respectively, were due on the Diamond Note 2 at December 31, 2022. The Diamond Note 2 was in default at December 31, 2022. Diamond Note 3 On April 27, 2022, Diamond Note 4 On May 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 4”). The Diamond Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 4 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 4, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 4. In addition, Mr. Diamond received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,960 at the date of issuance, and 1,930 shares of common stock with a value of $3,160; these amounts were recorded as discounts on the Diamond Note 4. Interest in the amount of $3,245 was accrued on the Diamond Note 4 during the year ended December 31, 2022. Discounts in the amount of $17,885 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,245, respectively, were due on the Diamond Note 4 at December 31, 2022. The Diamond Note 4 was in default at December 31, 2022. Diamond Note 5 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 5”). The Diamond Note 5 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 5 was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 5, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 5 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 5 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 5, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 5. In addition, Mr. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the Diamond Note 5. Interest in the amount of $3,929 was accrued on the Diamond Note 5 during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the Diamond Note 5 at December 31, 2022. The Diamond Note 5 was in default at December 31, 2022. Lindstrom Note 1 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1. Interest in the amount of $2,750 was accrued on the Lindstrom Note 1 during the year ended December 31, 2022. Discounts in the amount of $14,879 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $45,294 and $2,750, respectively, were due on the Lindstrom Note 1 at December 31, 2022. The Lindstrom Note 1 was in default at December 31, 2022. Dobbertin Note 1 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note. Interest in the amount of $1,179 was accrued on the Dobbertin Note during the year ended December 31, 2022. Discounts in the amount of $6,377 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $19,412 and $1,179, respectively, were due on the Dobbertin Note at December 31, 2022. The Dobbertin Note was in default at December 31, 2022. Howe Note 2 On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 2”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 2 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 2, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 2. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $10,965 at the date of issuance, and 2,460 shares of common stock with a value of $22,440; these amounts were recorded as discounts to the Howe Note 2. Interest in the amount of $18,888 was accrued on the Howe Note 2 during the year ended December 31, 2022. Discounts in the amount of $108,405 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $18,888, respectively, were due on the Howe Note 2 at December 31, 2022. The Howe Note 2 was in default at December 31, 2022. Howe Note 3 On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 3”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 3 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 3 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 3, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 3. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $9,945 at the date of issuance, and 2,460 shares of common stock with a value of $12,495; these amounts were recorded as discounts to the Howe Note 3. Interest in the amount of $15,436 was accrued on the Howe Note 3 during the year ended December 31, 2022. Discounts in the amount of $97,440 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $15,436, respectively, were due on the Howe Note 3 at December 31, 2022. The Howe Note 3 was in default at December 31, 2022. Iturregui Note 1 On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 in a related party transaction to Juan Carlos Iturregui, a member of the Company’s Board of Directors (the “Iturregui Note 1”). The Iturregui Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Iturregui Note 1 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Iturregui Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Iturregui Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Iturregui reasonably believes contains a term that is more favorable than those in the Iturregui Note 1, the Company shall notify Mr. Iturregui of such term, and such term, at the option of Mr. Iturregui, shall become a part of the Iturregui Note 1. In addition, Mr. Iturregui received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $975 at the date of issuance, and 242 shares of common stock with a value of $1,225; these amounts were recorded as discounts to the Iturregui Note 1. Interest in the amount of $1,313 was accrued on the Iturregui Note 1 during the year ended December 31, 2022. Discounts in the amount of $8,464 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,089 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,313, respectively, were due on the Iturregui Note 1 at December 31, 2022. Howe Note 4 On August 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $200,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 4”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 4 was $170,000; the amount payable at maturity will be $200,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 4, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 4. In addition, Mr. Howe received 1,640 shares of common stock with a value of $10,775; this amount was recorded as a discount to the Howe Note 4. Interest in the amount of $8,756 was accrued on the Howe Note 4 during the year ended December 31, 2022. Discounts in the amount of $60,775 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $220,000 and $8,756, respectively, were due on the Howe Note 4 at December 31, 2022. The Howe Note 4 was in default at December 31, 2022. November 29, 2022 Notes On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, the Company’s CFO and Board Member; (2) Lawrence Diamond, the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, Board Member; (6) Jenny Lindstrom, the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”). The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 12. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022. Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022. See notes 12 and 16. These amounts are reflected in the table below: December 31, 2022 December 31, 2021 Notes Payable $ 2,799,632 $ 1,100,000 Less: Discount $ (22,670 ) $ (511,568 ) Notes payable – net of discounts $ 2,776,962 $ 588,432 Current Portion, net of discount $ 2,776,962 $ 588,432 Long-term portion, net of discount $ - $ - Interest expense on notes payable – related parties was $1,243,639 and $0 for the years ended December 31, 2022 and 2021, respectively Accrued interest on notes payable – related parties was $198,753 and $0 at December 31, 2022 and 2021, respectively. |
Derivative Liabilities
Derivative Liabilities | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Text Block [Abstract] | |
Derivatives and Fair Value [Text Block] | Note 11: Derivative Liabilities Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Lattice Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructure, and at each period end. Derivative liability activity for the years ended December 31, 2022 and 2021 is summarized in the table below: December 31, 2020 $ 807,683 Settled upon conversion or exercise (1,302,138 ) Loss on revaluation 494,455 December 31, 2021 $ - True-up features issued 192,375 Settled upon conversion or exercise (310,641 ) Loss on revaluation 687,178 December 31, 2022 $ 568,912 The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations: December 31, 2022 Volatility 95.1% to 123.2 % Stock Price $ 1.06 to 3.50 Risk-free interest rates 4.35% to 4.37 % Term (years) 0.73 to 0.86 Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation: ● The stock price would fluctuate with the Company projected volatility. ● The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation. ● The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1. ● In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions. ● Discount rates were based on risk free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation. |
Stockholders_ Equity (Deficit)
Stockholders’ Equity (Deficit) | 12 Months Ended |
Dec. 31, 2022 | |
Stockholders' Equity Note [Abstract] | |
Equity [Text Block] | Note 12: Stockholders Equity (Deficit) Common Stock The Company has authorized 500,000,000 shares of common stock, par value $0.01; 4,630,372 and 4,266,669 shares were issued and outstanding at December 31, 2022 and December 31, 2021, respectively. On December 12, 2022, the Company effected one-for-fifty reverse-split of its common stock. The number of shares of common stock outstanding immediately before the reverse-split was 231,374,330; the number of shares of common stock immediately following the reverse-split was 4,630,372, a decrease of 226,743,958 shares. Common Stock Transactions During the Year Ended December 31, 2022 On January 12, 2022, the Company entered into a settlement agreement with an ex-employee. Pursuant to the terms of this agreement, the Company agreed to pay the amount of $19,032 for accrued salary, and the employee returned to the Company for cancellation 8,000 shares of common stock previously issued as compensation. These shares were valued at par value of $0.01 or a total value of $80; the Company recorded a gain on cancellation of these shares in the amount of $15,032. The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) on January 7, 2022 (the “Gardner Equity Agreement”). Pursuant to Gardner Equity Agreement, the Company issued shares of restricted common stock to Gardner in exchange for the Company Debt Obligations, as defined below. The Gardner Equity Agreement settled for certain accounts payable amounts owed by the Company to Gardner. The Gardner Equity Agreement also settled accrued interest and penalties on the amounts due through January 5, 2022, as well as interest payments on amounts incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount was $500,000, the Additional Costs were $294,912 and the conversion price was $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. On March 22, 2022 and March 31, 2022, the Company issued an aggregate 30,835 shares of common stock as waiver fees to holders of the Series C and Series D Preferred Stock for their waivers of certain covenants as set forth and defined in the Series C and Series D Certificates of Designations. The Company valued these shares at their contractual price of $12.50 per share and recorded the amount of $385,431 as waiver fees. The Company recorded an aggregate gain upon issuance of these shares in the amount of $198,273 based on the market price of the Company’s common stock on the date of issuance. On March 31, 2022, the Company issued 34,400 Commitment Fee Shares to AJB Capital Investors, LLC. A Monte Carlo model was used to value the warrants and call features, and a probability weighted expected return model was used to value the True-Up Provision. The contractual price of the common stock $12.50 per share; valuation purposes, the common stock was valued at the market price on the date of the transaction of $6.35 per share. The discount on the notes due to the Commitment Fee Shares and warrants was valued at $349,914. The Company recorded the amount of $226,106 to additional paid-in capital pursuant to this transaction. On March 31, 2022, the Company issued 7,648 shares of common stock at a price of $12.50 per share which were previously subscribed for the conversion of accounts payable in the amount of $95,558. On April 27, 2022, the Company issued 14,400 shares of stock to Cavalry Fund 1 LP at a price of $6.35 per share for a total value of $91,440 as compensation for the waiver of certain covenants as set forth in the Series C Certificate of Designation. The Company recorded a gain in the amount of $88,560 on this transaction. On April 27, 2022, the Company issued 1,929 shares of common stock with a contract price of $12.50 per share or $24,118 and a grant date market value of $8.00 or $15,434 to Larry Diamond, it’s Chief Executive as commitment shares as set forth and defined in Diamond Note 3. The Company recorded these shares at their relative fair value of the components of Diamond Note 3, or $16,200, and recorded a loss in the amount of $765 on this transaction. The Company also issued five-year warrants to purchase 1,929 shares of common stock at a price of $12.50 to Mr. Diamond pursuant to Diamond Note 3. On May 1, 2022, the Company issued 15,000 shares of common stock to a service provider at a price of $6.88 per share. On May 10, 2022, the Company entered into a securities purchase agreement with Kishon Investments, LLC with respect to the sale and issuance of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares of the Company’s common stock , (ii) promissory note in the principal amount of $277,777 due on November 10, 2022, and (iii) warrants to purchase up to 5,556 shares of the common stock . The note and warrants were issued on May 10, 2022 and were held in escrow pending effectiveness of the Purchase Agreement. Pursuant to the terms of the purchase agreement, the initial shares were issued at a value of $159,259, the note was issued in the principal amount of $277,777 for a purchase price of $250,000, resulting in the original issue discount of $27,777; and the warrants were issued, with an initial exercise price of $12.50 per share, subject to adjustment. On May 18, 2022, the Company issued 386 shares of common stock to Larry Diamond, it’s Chief Executive Officer at a contractual price of $12.50 per share and a market price at issuance date of $7.585 per share as commitment shares as set forth and defined in Diamond Note 4. The Company recorded these shares at their relative fair value of the components of Diamond Note 4, or $3,160 and recorded a loss in the amount of $249 on this transaction. The Company also issued five-year warrants to purchase 386 shares of common stock at a price of $12.50 to Mr. Diamond pursuant to Diamond Note 4. On May 23, 2022, the Company issued 386 shares of common stock to Jessica Finnegan at a contractual price of $12.50 per share and a market price at issuance date of $8.97 per share as commitment shares as set forth and defined in Finnegan Note 1. The Company recorded these shares at their relative fair value of the components of Finnegan Note 1, or $3,240, and recorded a gain in the amount of $222 on this transaction. The Company also issued five-year warrants to purchase 386 shares of common stock at a price of $12.50 to Ms. Finnegan pursuant to Finnegan Note 1. On May 26, 2022, the Company issued 1,688 shares of common stock to the May 26 Lenders at a contractual price of $12.50 per share and a market price at issuance date of $7.585 per share as commitment shares as set forth and defined in the May 26, 2022 Notes. The Company recorded these shares at their relative fair value of the components of the May 26 Note, or $14,175, and recorded a loss in the amount of $1,369 on these transactions. The Company also issued five-year warrants to purchase 1,688 shares of common stock at a price of $25.00 to the May 26 Lenders pursuant to the May 26, 2022. On June 7, 2022, the Company issued 8,103 shares of common stock at a price of $12.50 per share to investors for accumulated dividends on Series X Preferred Stock. See Note 12. On June 9, 2022, the Company issued 7,284 shares of common stock to the June 9 Lenders at a contractual price of $12.50 per share and a market price at issuance date of $7,425 per share as commitment shares as set forth and defined in the June 9 Notes. The Company recorded these shares at the relative fair value of the components of June 9 Notes, or $66,400, and recorded an aggregate loss in the amount of $9,356 on these transactions. The Company also issued five-year warrants to purchase 7,284 shares of common stock at a price of $25.00 to the May 26 Lenders pursuant to the June 9 notes. On June 22, 2022, the Company issued 4,824 shares of common stock at fair value of $10.45 per share to Dragon Dynamic at a fair value of $10.45 per share as a commitment fee. On June 22, 2022, the Company issued 12,741 shares of common stock at fair value of $10.45 per share to GS Capital at a fair value of $10.45 per share as a commitment fee. On June 22, 2022, the Company issued 8,600 shares of common stock at fair value of $10.45 per share to Anson East and an additional 25,800 shares of common stock at a fair value of $10.45 per share to Anson Investments as a commitment fee. On July 7, 2022, the Company issued 2,412 shares of common stock to William Mackay at a contractual price of $12.50 per share and a market price at issuance date of $7.445 per share as commitment shares as set forth and defined in the Mackay Note. The Company recorded these shares at their relative fair value of the components of Mackay Note, or $12,500, and recorded a gain in the amount of $5,456 on this transaction. The Company also issued five-year warrants to purchase 2,412 shares of common stock at a price of $12.50 to Mr. Mackay pursuant to the Mackay Note. On July 7, 2022, the Company issued 193 shares of common stock to Charlies Schrier at a contractual price of $12.50 per share and a market price at issuance date of $7.445 per share as commitment shares as set forth and defined in the Schrier Note. The Company recorded these shares at their relative fair value of the components of Schrier Note, or $1,000, and recorded a gain in the amount of $436 on this transaction. The Company also issued five-year warrants to purchase 193 shares of common stock at a price of $25.00 to Mr. Schrier pursuant to the Schrier Note. On July 21, 2022, the Company issued 241 shares of common stock to Juan Carlos Iturregui, a related party, at a contractual price of $12.50 per share and a market price at issuance date of $7.225 per share as commitment shares as set forth and defined in the Iturregui Note. The Company recorded these shares at their relative fair value of the components of Schrier Note, or $1,225, and recorded a gain in the amount of $518 on this transaction. The Company also issued five-year warrants to purchase 241 shares of common stock at a price of $25.00 to Mr. Iturregui pursuant to the Iturregui Note. On July 21, 2022, the Company issued 2,460 shares of common stock to the Michael C. Howe Living Trust, a related party, at a contractual price of $12.50 per share and a market price at issuance date of $7.225 per share as commitment shares as set forth and defined in the Howe Note 3. The Company recorded these shares at their relative fair value of the components of Howe Note 3, or $12,495, and recorded a gain in the amount of $5,729 on this transaction. The Company also issued five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 to the Michael C. Howe Living Trust pursuant to the Howe Note 3. On July 26, 2022, the Company issued 482 shares of common stock to Eric S. Nommsen at a contractual price of $12.50 per share and a market price at issuance date of $6.84 per share as commitment shares as set forth and defined in the Nommsen Note. The Company recorded these shares at their relative fair value of the components of Nommsen Note, or $2,350, and recorded a gain in the amount of $949 on this transaction. The Company also issued five-year warrants to purchase 482 shares of common stock at a price of $25.00 to Mr. Nommsen pursuant to the Nommsen Note. On July 27, 2022, the Company issued 482 shares of common stock to James H. Caplan at a contractual price of $12.50 per share and a market price at issuance date of $6.935 per share as commitment shares as set forth and defined in the Caplan Note. The Company recorded these shares at their relative fair value of the components of the Caplan Note, or $2,350, and recorded a gain in the amount of $995 on this transaction. The Company also issued five-year warrants to purchase 482 shares of common stock at a price of $25.00 to Mr. Caplan pursuant to the Caplan Note. On August 4, 2022, the Company issued a total of 241 shares of common stock to Jessica, Kevin C., Brody, Isabella, and Jack Finnegan at a contractual price of $25.00 per share and a market price at issuance date of $6.42 per share as commitment shares as set forth and defined in the Finnegan Note 3. The Company recorded these shares at their relative fair value of the components of the Finnegan Note 3, or $1,000, and recorded a gain in the amount of $448 on this transaction. The Company also issued five-year warrants to purchase a total of 241 shares of common stock at a price of $25.00 to the holders of the Finnegan Note 3. On August 4, 2022, the Company issued 984 shares of common stock to Jack Enright at a contractual price of $12.50 per share and a market price at issuance date of $6.42 per share as commitment shares as set forth and defined in the Caplan Note. The Company recorded these shares at their fair value of $6,317. On August 4, 2022, the Company issued 12,064 shares of common stock to a service provider as payment for investor relations services. The transaction was effective August 1, 2022 and has a six month term. The shares were valued at the closing price of the Company’s common stock on August 4, 2022, of $6.42 per share or $77,448. On August 18, 2022, the Company issued 1,640 shares of common stock to the Michael C. Howe Living Trust, a related party, at a contractual price of $12.50 per share and a market price at issuance date of $6.57 per share as commitment shares as set forth and defined in the Howe Note 4. The Company recorded these shares at their fair value of $10,775. On September 2, 2022, the Company issued 582 shares of common stock to John Mitchell at a contractual price of $12.50 per share and a market price at issuance date of $5.365 per share as commitment shares as set forth and defined in the Mitchell Note. The Company recorded these shares at their fair value of $3,124. On September 2, 2022, the Company issued 492 shares of common stock to Frank Lightmas at a contractual price of $12.50 per share and a market price at issuance date of $5.365 per share as commitment shares as set forth and defined in the Lightmas Note. The Company recorded these shares at their fair value of $2,640. On September 2, 2022, the Company issued 246 shares of common stock to Lisa Lewis at a contractual price of $12.50 per share and a market price at issuance date of $5.365 per share as commitment shares as set forth and defined in the Lewis Note. The Company recorded these shares at their fair value of $1,320. On September 2, 2022, the Company issued 246 shares of common stock to Sharon Goff at a contractual price of $12.50 per share and a market price at issuance date of $5.65 per share as commitment shares as set forth and defined in the Goff Note. The Company recorded these shares at their fair value of $1,320. On September 9, 2022, the Company issued 820 shares of common stock to Cliff Hagan at a contractual price of $12.50 per share and a market price at issuance date of $5.75 per share as commitment shares as set forth and defined in the Hagan Note. The Company recorded these shares at their fair value of $4,715. On September 14, 2022, the Company issued 1,640 shares of common stock to Darling Capital at a contractual price of $12.50 per share and a market price at issuance date of $6.60 per share as commitment shares as set forth and defined in the Darling Capital Note. The Company recorded these shares at their fair value of $10,824. On September 15, 2022, the Company issued 410 shares of common stock to Mack Leath at a contractual price of $12.50 per share and a market price at issuance date of $6.995 per share as commitment shares as set forth and defined in the Leath Note. The Company recorded these shares at their fair value of $2,868. On October 1, 2022, the Company issued 6,329 shares of common stock at a price of $16.00 per share to a service provider. On November 18, 2022, the Company issued 91,328 shares of common stock to AJB in settlement of the AJB True-up Obligation. See note 9. Common Stock Transactions During the Year Ended December 31, 2021 On January 4, 2021, the Company issued 82,475 shares of common stock at a price of $0.60 per share pursuant to the conversion of $45,000 of principal and $4,485 of accrued interest in Eagle Equities Note 4. On January 6, 2021, the Company issued 70,119 shares of common stock at a price of $0.612 per share pursuant to the conversion of $39,000 of principal and $3,913 of accrued interest in Eagle Equities Note 4. On January 11, 2021, the Company issued 89,270 shares of common stock at a price of $0.612 per share pursuant to the conversion of $50,000 of principal and $4,633 of accrued interest in Eagle Equities Note 5. On January 14, 2021, the Company issued 86,388 shares of common stock at a price of $0.633 per share pursuant to the conversion of $50,000 of principal and $4,683 of accrued interest in Eagle Equities Note 5. On January 21, 2021, the Company issued 128,992 shares of common stock at a price of $0.77 per share pursuant to the conversion of $93,000 of principal and $6,324 of accrued interest in Eagle Equities Note 6. On January 28, 2021, the Company issued 145,702 shares of common stock at a price of $0.7875 per share pursuant to the conversion of $107,200 of principal and $7,540 of accrued interest in Eagle Equities Note 6. On February 1, 2021, the Company issued 133,440 shares of common stock in a private placement (the "2021 Private Placement”) at a price of $12.50 per share for cash proceeds of $1,668,000. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 7 whereby the Company issued 23,683 shares of common stock at a price of $12.492 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 8 whereby the Company issued 12,792 shares of common stock at a price of $11.926 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 9 whereby the Company issued 12,104 shares of common stock at a price of $12,492 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 10 whereby the Company issued 21,903 shares of common stock at a price of $11,874 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 22, 2021, the Company issued 6,720 shares of common stock for the exercise of options at a price of $15.00 per share. On March 11, 2021, the Company issued 12,000 shares of common stock to four officers of The Good Clinic in exchange for 4,800 shares of Series A Preferred Stock. The 4,800 shares of Series A Preferred Stock were cancelled. On March 17, 2021, the Company issued 6,000 shares of common stock at a price of $15.50 per share to a service provider. On March 23, 2021, the Company issued 9,227 shares of common stock at a price of $13.00 per share to the underwriters of the 2021 Private Placement. On April 19, 2021, the Company issued 39 shares of common stock for professional fees which had been performed in a prior period. The Company recorded these shares at the par value of $0.01 per share. On May 4 through May 26, 2021, the Company issued 84,748 shares of common stock for the conversion of 1,059,356 shares of Series C Preferred Stock at a price of $12.50 per share. On May 12, 2021, the Company issued 50,000 shares of common stock at a price of $15.00 per share for the exercise of stock options by an investor. On June 10 through June 29, 2021, the Company issued 102,333 shares of common stock at a price of $15.00 per share for the exercise of stock options by officers and directors. On June 23, 2021, the Company cancelled 40,000 shares of common stock held by an ex-officer in connection with a settlement agreement. The cancellation of these shares was recorded at the par value of $0.01 per share. Also, in connection with the settlement agreement, the Company issued 12,759 shares to the ex-officer at the market price of $10.00 per share. On August 17, 2021, accrued liabilities in the amount of $156,441 were converted to 12,515 shares of common stock. 9,589 shares were issued during December 2021 and the remaining 2,926 shares was not issued and recorded in common stock subscribed as of December 31, 2021. Among the 12,515 shares, 6,256 restricted shares of the Company’s common stock was issued to settled $78,200 cash compensation owed to the Company’s Chief Executive Officer for services rendered to the Company prior to 2021. Between August 11, 2021 and September 2, 2021, the Company issued 80,000 shares of the Company common stock in connection with the conversion of Series C preferred stock issued in the first quarter. Also, during the year ended December 31, 2021, the Company charged the amount of $13,032 to operations in connection with the vesting of stock granted to its officers, employees, and board members; the Company also charged the amount of $676,423 to operations in connection with the vesting of options granted to its officers, employees, and board members. Preferred Stock We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, and 27,324 shares as Series X Preferred Stock. Series A Preferred Stock The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at December 31, 2022 and 2021. Series A Preferred Stock Transactions During the Year Ended December 31, 2022 None. Series A Preferred Stock Transactions During the Year Ended December 31, 2021 During the year ended December 31, 2021, the Company accrued dividends in the amount of $1,000 on the Series A Preferred Stock. On March 11, 2021, the Company issued 600,000 shares of common stock to the four officers of The Good Clinic in exchange for the previously issued Series A Preferred Stock and accrued dividends. The Series A preferred stock was canceled and there are no Series A Preferred shares outstanding at December 31, 2021. Series C Preferred Stock The Series C Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Fully Paid and Nonassessable Series C Preferred Stock Transactions During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company accrued dividends on the Series C Preferred Stock in the amount of $66,447. The Company also adjusted the number of shares of Series C Preferred Stock outstanding by an increase in the amount of 98,064 shares in connection with previous conversions of Series C Preferred Stock to common stock; the amount of $981 was charged to additional paid-in capital pursuant to this adjustment. Series C Preferred Stock Transactions During the Year Ended December 31, 2021 On March 25, 2021, the Company sold 3,000,000 shares of its Series C Preferred Stock along with (i) five-year warrants to purchase 6,300,000 shares of the Company’s common stock at a price of $0.50 per share, and (ii) five On May 4 through May 26, 2021, 1,059,356 shares of Series C Preferred Stock were converted at a price of $0.25 per share to 4,237,424 shares of common stock. Between August 11,2021 through September 2, 2021, 1,000,000 shares of Series C Preferred Stock were converted at a price of $0.25 per share to 4,000,001 shares of common stock. During the year ended December 31, 2021, the Company accrued dividends on the Series C Preferred Stock in the amount of $87,059. Series D Preferred Stock The Series D Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Series D Preferred Stock Transactions During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company accrued dividends on the Series D Preferred Stock in the amount of $195,299. Series D Preferred Stock Transactions During the Year Ended December 31, 2021 On October 18, 2021, the Company sold 2,050,000 shares of Series D Preferred Stock and (i) five-year warrants to acquire 85,050 shares of the Company’s common stock at a price of $25.00 per shares, and (ii) five On November 10, 2021, the Company sold 1,075,000 shares of Series D Preferred Stock and (i) five-year warrants to acquire 45,150 shares of the Company’s common stock at a price of $25.00 per shares, and (ii) five During the year ended December 31, 2021, the Company accrued dividends on the Series D Preferred Stock in the amount of $35,327. Series E Preferred Stock On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are 0 shares of Series E Preferred Stock outstanding at December 31, 2022 and 2021. As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E. Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon. Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120 th th Series E Exchange Agreements During the year ended December 31, 2022, the Company entered into the following agreements to exchange certain debt and equity amounts for shares of Series E Preferred Stock (see notes 9, 10, and 16): On October 5, 2022, the Company entered into the Cavalry Exchange Agreement, pursuant to which Cavalry shall exchange (a) 1,000,000 shares of the Company’s Series C Convertible Preferred Stock (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock and (c) amounts owing under the Cavalry Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Cavalry Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Cavalry Exchange Agreement during the year ended December 31, 2022. See note 9 and 16. On October 7, 2022, the Company entered into the Mercer Exchange Agreement whereby Mercer shall exchange (a) 47,619 shares of the Company’s Series C Convertible Preferred Stock, (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock, and (c) amounts owing under the Mercer Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Mercer Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Mercer Exchange Agreement during the year ended December 31, 2022. See note 9. Amounts due under the Mercer Note 2 will also convert pursuant to the terms of the Mercer Exchange Agreement into shares of the Company’s series E Preferred Stock. See note 9 and 16. On October 10, 2022, the Company entered into the Pinz Exchange Agreement whereby Pinz shall exchange (a) 100,000 shares of the Company’s Series D Convertible Preferred Stock, and (b) amounts owing under the Pinz Note, for a number of Series E Convertible Preferred Stock equal to 150% of the principal amount of the Pinz Note, plus 150% of the stated value of the Series D Shares. No transactions occurred pursuant to the Pinz Exchange Agreement during the year ended December 31, 2022. See note 9 and 16. On October 18, 2022, the Company entered into separate exchange agreements with each of Anson East Master Fund LP and Anson Investments Master Fund LP (collectively, “Ansons”), (the “Ansons Exchange Agreements”). Pursuant to the Ansons Exchange Agreements, Ansons shall exchange an aggregate of 750,000 shares of the Company’s Series D Stock for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the stated value of the Series D Shares (the "Series E Exchange Value"), and the Funds have agreed to invest no less than an aggregate amount of $375,000 into the uplisting offering. No transactions occurred pursuant to the terms of the Ansons Exchange Agreements during the year ended December 31, 2022. See notes 9 and 16. On November 29, 2022, the Company entered into the November 29 Notes Exchange Agreements whereby amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022. See notes 10 and 16. Series X Preferred Stock The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of December 31, 2022 and December 31, 2021. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders. Series X Preferred Stock Transactions During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company accrued dividends on the Series X Preferred Stock in the amount of $60,564. Series X Preferred Stock Transactions During the Year Ended December 31, 2021 On June 23, 2021, 2,000 shares of Series X Preferred Stock were cancelled pursuant to a settlement agreement with an ex-officer. Stock Options The following table summarizes the options outstanding at December 31, 2022 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contract |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | Note 13: Income Taxes Deferred income taxes result from the temporary differences primarily attributable to amortization of intangible assets and debt discount and an accumulation of net operating loss carryforwards for income tax purposes with a valuation allowance against the carryforwards for book purposes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Included in deferred tax assets are Federal and State net operating loss carryforwards of approximately $9.7 million, which will expire through 2040. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Due to significant changes in the Company’s ownership, the Company’s future use of its existing net operating losses may be limited. The provision (benefit) for income taxes for the years ended December 31, 2022 and 2021 consist of the following: 2022 2021 Current $ - $ - Deferred - - Total $ - $ - For the years ended December 31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows: For the Years Ended December 31, 2022 2021 Expected tax at statutory rates $ (4,879,000 ) 21 % $ (2,351,000 ) 21 % Permanent Differences 1,610,000 7 % 692,000 6 % State Income Tax, Net of Federal benefit 380,000 2 % (612,000 ) 5 % Current Year Change in Valuation Allowance 2,137,000 9 % 2,291,000 20 % Prior Year True-Ups 752,000 3 % (20,000 ) 0 % Income tax expense $ - 0 % $ - 0 % Deferred income taxes reflect the tax impact of temporary differences between the amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. Deferred income taxes include the net tax effects of net operating loss (NOL) carryforwards and the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2022, and 2021 significant components of the Company’s deferred tax assets are as follows: For the Years Ended December 31, 2022 2021 Deferred Tax Assets (Liabilities): Accrued payroll $ 112,000 $ 22,000 ASC842-ROU Asset (68,000 ) (1,117,000 ) ASC842-ROU (Liability) 830,000 1,189,000 Loss from derivatives (130,000 ) (4,000 ) Waiver and commitment fee shares (32,000 ) - Stock based compensation (85,000 ) 398,000 Depreciation 33,000 (764,000 ) Net operating loss 9,679,000 8,478,000 Net deferred tax assets (liabilities) 10,339,000 8,202,000 Valuation allowance (10,339,000 ) (8,202,000 ) Net deferred tax assets (liabilities) $ - $ - |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Disclosures [Text Block] | Note 14: Fair Value of Financial Instruments The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at December 31, 2022 and 2021. December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 568,912 $ 568,912 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ - $ - |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Note 15: Commitments and Contingencies Legal From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 18, 2020, the Company’s former President and COO completed and applied on behalf of the Company to Bank of America, NA (“Bank of America”) for a PPP loan, which was subsequently approved. On April 25, 2020, the Company entered into an unsecured Promissory Note (the “Note”) with Bank of America for a loan in the original principal amount of $460,406, and the Company received the full amount of the loan proceeds on May 4, 2020. On July 21, 2020, Bank of America notified the Company in writing that it should not have received $440,000 of the loan proceeds disbursed under the Note. The Company investigated the terms of the application and discovered its former President had erroneously represented it was refinancing an Economic Injury Disaster Loan when no such loan had been received. Bank of America requested that the Company remit the funds received back to Bank of America. The Company negotiated the conversion of this to a 60 month note at 1% interest. We are currently in default on this note. If we are not successful in bringing this liability current, it could have a material adverse effect on our financial condition. On October 25, 2022, the company was notified that a vendor filed suit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 shares of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor. The Company has a number of legal situations involved with the winding down of its clinic business activities including claims regarding certain construction contracts and as a part of the process of cancellation of leases. The following is a summary as of the date of this filing: ● The Wayzata, MN clinic leases was terminated for a commitment to pay $25,000. ● The two Denver, Colorado clinic lease, known as Quincy and Radiant, possession has been relinquished to the landlords. The lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The Eagan clinic, aka Vikings clinic, gave up possession in January of 2023. The mechanics lien has been placed on the property was settled by the landlord in a confidential settlement with the lien holder. Mitesco is now in settlement negotiations with the landlord for the handling of lease obligations. ● The St. Paul clinic possession was relinquished in March 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The St. Louis Park clinic possession was relinquished in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The Maple Grove clinic eviction occurred in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The Northeast Minneapolis clinic, aka Nordhaus clinic, possession was relinquished in May 2023. There is no lien on the property. The handling of lease obligations remains in negotiations with the landlord. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | Note 16: Subsequent Events Common Stock Issued On January 23, 2023, the Company issued 150,000 shares of common stock at a price of $3.45 per share to a service provider. On January 23, 2023, the Company issued a total of 8,063 shares of common stock at a price of $4.33 per share to holders of the Series X Preferred Stock for accrued dividends. Larry Diamond, the Company’s Chief Executive Officer, received 666 of these shares. On February 15, 2023, the Company issued 9,846 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On February 21, 2023, the Company issued 150,000 shares of common stock at a price of $2.63 per share to a service provider. On March 1, 2023, the Company issued 13,555 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On March 9, 2023, the Company issued 15,265 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On March 28, 2023, the Company issued 18,472 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On April 4, 2023, the Company issued 94,738 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On May 5, 2023, the Company issued 2,952 shares of common stock at a price of $1.05 per share to a service provider. On May 5, 2023, the Company issued 2,552 shares of common stock to an investor at a price of $1.05 per share for satisfaction of accounts payable. On May 9, 2023, the Company issued 19,622 shares of common stock to Michael C. Howe, a related party, at a price of $0.94 per share to reimburse Mr. Howe for costs incurred in connection with a settlement agreement with a vendor. Spartan Capital Advisory Agreement On January 12, 2023 the Company entered into an advisory agreement with Spartan Capital (“Spartan”) pursuant to which Spartan will act as exclusive financial advisor in providing general financial advisory services to the Company. In consideration for the financial advisory services to be rendered thereunder, the Company will issue to Spartan 150,000 restricted common shares of the Company (“Common Stock”). In addition, the Company will issue to Spartan an additional 50,000 Common Stock within three business days of completion of a gross raise of at least $2,000,000. Sale of Series F Preferred Stock On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK Convertible Perpetual Preferred Stock (the “Series F”) with the Delaware Secretary of State. The number of shares of Series F designated is 140,000 and each share of Series F has a stated value equal to $1,000. Each share of Series F Preferred Stock shall have a par value of $0.01.Holders of the Series F are entitled to receive payment in kind dividends (“PIK Dividends”) at the quarterly rate of three-hundredths of one share outstanding per Series F Share. The Series F can be converted at the option of the Series F shareholder into shares of the Company’s common stock at a price equal to 65% of the Volume Weighted Average Price (“VWAP”) on the conversion date. Purchase Agreement On April 11, 2023, the Company entered into securities purchase agreements (each a “Purchase Agreement”) with investors providing for the sale and issuance of (i) Series F 12% PIK Convertible Perpetual Preferred Stock, par value $0.01 per share (the “Series F Shares”) and (ii) warrants to purchase shares of Common Stock (the “Warrants,” and together with the Series F Shares, the “Securities”). The closing on the first tranche of the offering resulted in gross proceeds to the Company of $650,000. The net proceeds to the Company from the first tranche of the offering were $511,000, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general operating expenses. In connection with the Purchase Agreement, the Company also entered into a registration rights agreement. Exchange Agreements Also in connection with the Purchase Agreement, the Company entered into separate exchange agreements pursuant to which the investors in the Series E Preferred Stock exchanged certain securities, as defined in each individual Exchange Agreement, for a number Series F Shares (based on their liquidation preference of $1,000) equal to 120%, 165% or 230%, depending on whether the investor is investing additional funds into the bridge financing, of the “Principal Amount,” “Stated Value” and/or liquidation preference of the Exchange Securities (including any payoff bonus, accrued dividends or interest). Appointment of Ms. Sheila Schweitzer as Chairperson of the Board of Directors and President, Chief Operating Officer Effective June 1, 2023, the Board of Directors appointed Ms. Sheila Schweitzer to the position of President and Chief Operating Officer. Ms. Schweitzer will receive a salary in the amount of $200,000 per year. Her employment agreement is for a period of one year. Effective June 06, 2023, the Board of Directors of the Company appointed Ms. Schweitzer who has been a member of the Board of Directors since 2021, to the position of Chairperson, replacing Mr. Tom Brodmerkel, who has completed his term as Chair. Mr. Brodmerkel will remain as Chief Financial Officer and continue to serve as a member of the Company’s Board of Directors. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Accounting |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates - |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash - |
Property, Plant and Equipment, Policy [Policy Text Block] | Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease |
Construction in Progress, Policy [Policy Text Block] | Construction in Progress - |
Revenue [Policy Text Block] | Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. |
Share-Based Payment Arrangement [Policy Text Block] | Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition. |
Convertible Instruments, Policy [Policy Text Block] | Convertible Instruments |
Derivatives, Policy [Policy Text Block] | Derivative Financial Instruments |
Warrants, Policy [Policy Text Block] | Common Stock Purchase Warrants- |
Stockholders' Equity, Policy [Policy Text Block] | Stockholders Equity- |
Earnings Per Share, Policy [Policy Text Block] | Per Share Data- |
Income Tax, Policy [Policy Text Block] | Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. |
Business Combinations Policy [Policy Text Block] | Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets- |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Standards In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock, and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2022, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The adoption of this new guidance did not have a material effect on our consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Accounting Policies [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy: Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease |
Net Loss Per Share Applicable_2
Net Loss Per Share Applicable to Common Shareholders (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The following table sets forth the computation of loss per share for the years ended December 31, 2022 and 2021, respectively: For the Years Ended December 31, 2022 2021 Numerator: Net loss applicable to common shareholders $ (23,558,439 ) $ (11,226,366 ) Denominator: Weighted average common shares outstanding 4,451,962 4,060,005 Net loss per share: Basic and diluted $ (5.29 ) $ (2.77 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | The Company excluded all common equivalent shares for warrants, options, and convertible instruments from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2022 and 2021, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2022 2021 Options 310,692 374,924 Warrants 672,334 596,400 Preferred Stock 347,652 347,652 Accrued Interest 42,002 17,443 Total 1,372,680 1,336,419 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Payables and Accruals [Abstract] | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | Accounts payable and accrued liabilities consisted of the following at December 31, 2022 and 2021: December 31, December 31, 2022 2021 Trade accounts payable $ 6,761,793 $ 3,933,305 Accrued payroll and payroll taxes 590,915 23,554 Other 507 19,205 Total accounts payable and accrued liabilities $ 7,353,215 $ 3,976,064 |
Right to Use Assets and Lease_2
Right to Use Assets and Lease Liabilities - Operating Leases (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Text Block [Abstract] | |
Lease, Cost [Table Text Block] | Right to use assets – operating leases are summarized below: December 31, 2022 December 31, 2021 Right to use assets, net $ 544,063 $ 3,886,866 December 31, 2022 December 31, 2021 Lease liability $ 4,379,724 $ 4,134,802 Less: current portion (442,866 ) (161,838 ) Lease liability, non-current $ 3,936,858 $ 3,972,964 |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | Maturity analysis under these lease agreements are as follows: For the period ended December 31, 2023 $ 945,102 For the period ended December 31, 2024 884,990 For the period ended December 31, 2025 906,666 For the period ended December 31, 2026 926,988 For the period ended December 31, 2027 946,745 Thereafter 1,939,476 Total $ 6,549,967 Less: Present value discount (2,170,243 ) Lease liability $ 4,379,724 |
Notes Payable (Tables)
Notes Payable (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Notes Payable (Tables) [Line Items] | |
Schedule of Debt [Table Text Block] | These amounts are reflected in the table below: December 31, 2022 December 31, 2021 Notes Payable $ 5,144,742 $ - Less: Discount (32,040 ) Notes payable - net of discount $ 5,112,702 $ - Current Portion, net of discount $ 5,112,702 $ - Long-term portion, net of discount $ - $ - |
Related Party [Member] | |
Notes Payable (Tables) [Line Items] | |
Schedule of Debt [Table Text Block] | These amounts are reflected in the table below: December 31, 2022 December 31, 2021 Notes Payable $ 2,799,632 $ 1,100,000 Less: Discount $ (22,670 ) $ (511,568 ) Notes payable – net of discounts $ 2,776,962 $ 588,432 Current Portion, net of discount $ 2,776,962 $ 588,432 Long-term portion, net of discount $ - $ - |
Derivative Liabilities (Tables)
Derivative Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Disclosure Text Block [Abstract] | |
Schedule of Derivative Instruments [Table Text Block] | Derivative liability activity for the years ended December 31, 2022 and 2021 is summarized in the table below: December 31, 2020 $ 807,683 Settled upon conversion or exercise (1,302,138 ) Loss on revaluation 494,455 December 31, 2021 $ - True-up features issued 192,375 Settled upon conversion or exercise (310,641 ) Loss on revaluation 687,178 December 31, 2022 $ 568,912 |
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] | The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations: December 31, 2022 Volatility 95.1% to 123.2 % Stock Price $ 1.06 to 3.50 Risk-free interest rates 4.35% to 4.37 % Term (years) 0.73 to 0.86 |
Stockholders_ Equity (Deficit)
Stockholders’ Equity (Deficit) (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Stockholders' Equity Note [Abstract] | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | The following table summarizes the options outstanding at December 31, 2022 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 1.50-16.00 310,692 7.97 $ 10.01 136,303 $ 7.89 310,692 7.97 $ 10.01 136,303 $ 7.89 |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Transactions involving stock options are summarized as follows: Shares Weighted- Average Exercise Price ($) (A) Outstanding at December 31, 2020 269,078 $ 1.50 Granted 285,900 13.00 Cancelled/Expired (7,000 ) 1.50 Outstanding at December 31, 2021 366,591 $ 10.29 Granted 4,000 $ 12.50 Cancelled/Expired (59,899 ) $ 12.18 Exercised - - Outstanding at December 31, 2022 310,692 $ 10.01 Options vested and exercisable 136,303 $ 7.89 |
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The Company valued stock options during the years ended December 31, 2022 and 2021 using the Black-Scholes valuation model utilizing the following variables: December 31, December 31, 2022 2021 Volatility 134.9% to 149.9 % 153.5% to 183.5 % Dividends $ - $ - Risk-free interest rates 2.82% to 4.25 % 0.820% to 1.69 % Term (years) 5.00 5.00-6.5 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | The following table summarizes the warrants outstanding at December 30, 2022 and the related prices for the warrants to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2020 - $ - Granted 596,400 $ 31.25 Exercised - $ - Outstanding at December 31, 2021 596,400 $ 31.25 Granted 75,934 $ 26.21 Exercised - $ - Outstanding at December 31, 2022 672,334 $ 30.68 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | The provision (benefit) for income taxes for the years ended December 31, 2022 and 2021 consist of the following: 2022 2021 Current $ - $ - Deferred - - Total $ - $ - |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | For the years ended December 31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows: For the Years Ended December 31, 2022 2021 Expected tax at statutory rates $ (4,879,000 ) 21 % $ (2,351,000 ) 21 % Permanent Differences 1,610,000 7 % 692,000 6 % State Income Tax, Net of Federal benefit 380,000 2 % (612,000 ) 5 % Current Year Change in Valuation Allowance 2,137,000 9 % 2,291,000 20 % Prior Year True-Ups 752,000 3 % (20,000 ) 0 % Income tax expense $ - 0 % $ - 0 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | As of December 31, 2022, and 2021 significant components of the Company’s deferred tax assets are as follows: For the Years Ended December 31, 2022 2021 Deferred Tax Assets (Liabilities): Accrued payroll $ 112,000 $ 22,000 ASC842-ROU Asset (68,000 ) (1,117,000 ) ASC842-ROU (Liability) 830,000 1,189,000 Loss from derivatives (130,000 ) (4,000 ) Waiver and commitment fee shares (32,000 ) - Stock based compensation (85,000 ) 398,000 Depreciation 33,000 (764,000 ) Net operating loss 9,679,000 8,478,000 Net deferred tax assets (liabilities) 10,339,000 8,202,000 Valuation allowance (10,339,000 ) (8,202,000 ) Net deferred tax assets (liabilities) $ - $ - |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 12 Months Ended |
Dec. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Derivative Liabilities at Fair Value [Table Text Block] | The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at December 31, 2022 and 2021. December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 568,912 $ 568,912 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ - $ - |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Accounting Policies [Abstract] | ||
Cash and Cash Equivalents, at Carrying Value | $ 35,623 | $ 1,164,483 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment | Dec. 31, 2022 |
Office Equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 3 years |
Office Equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 5 years |
Furniture and Fixtures [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 3 years |
Furniture and Fixtures [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 7 years |
Machinery and Equipment [Member] | Minimum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 3 years |
Machinery and Equipment [Member] | Maximum [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Useful Life | 10 years |
Leasehold Improvements [Member] | |
Property, Plant and Equipment [Line Items] | |
Property, Plant and Equipment, Estimated Useful Lives | Term of lease |
Net Loss Per Share Applicable_3
Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Numerator: | ||
Net loss applicable to common shareholders | $ (23,558,439) | $ (11,226,366) |
Denominator: | ||
Weighted average common shares outstanding | 4,451,962 | 4,060,005 |
Net loss per share: | ||
Basic and diluted | $ (5.29) | $ (2.77) |
Net Loss Per Share Applicable_4
Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 1,372,680 | 1,336,419 |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 310,692 | 374,924 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 672,334 | 596,400 |
Preferred Stock [Member] | Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 347,652 | 347,652 |
Accrued Interest [Member] | Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 42,002 | 17,443 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Liabilities (Details) - Gardner Agreement [Member] | Jan. 05, 2022 USD ($) $ / shares shares |
Accounts Payable and Accrued Liabilities (Details) [Line Items] | |
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares | $ 12.5 |
Restricted Stock [Member] | |
Accounts Payable and Accrued Liabilities (Details) [Line Items] | |
Common Stock, Shares Authorized (in Shares) | shares | 63,593 |
Accounts Payable [Member] | |
Accounts Payable and Accrued Liabilities (Details) [Line Items] | |
Debt Conversion, Original Debt, Amount | $ 500,000 |
Additional Costs [Member] | |
Accounts Payable and Accrued Liabilities (Details) [Line Items] | |
Debt Conversion, Original Debt, Amount | $ 294,913 |
Accounts Payable and Accrued _4
Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Schedule Of Accounts Payable And Accrued Liabilities Abstract | ||
Trade accounts payable | $ 6,761,793 | $ 3,933,305 |
Accrued payroll and payroll taxes | 590,915 | 23,554 |
Other | 507 | 19,205 |
Total | $ 7,353,215 | $ 3,976,064 |
Right to Use Assets and Lease_3
Right to Use Assets and Lease Liabilities - Operating Leases (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Disclosure Text Block [Abstract] | ||
Lessee, Operating Lease, Remaining Lease Term | 7 years 6 months | |
Operating Lease, Expense | $ 860,705 | $ 351,854 |
Operating Lease, Right-of-Use Asset, Periodic Reduction | 357,700 | $ 162,276 |
Impairment, Lessor Asset under Operating Lease | $ 3,185,591 | |
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent | 12% | 12% |
Operating Lease, Weighted Average Remaining Lease Term | 84 months | 92 months 3 days |
Right to Use Assets and Lease_4
Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lease, Cost - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Lease, Cost [Abstract] | ||
Right to use assets, net | $ 544,063 | $ 3,886,866 |
Lease liability | 4,379,724 | 4,134,802 |
Less: current portion | (442,866) | (161,838) |
Lease liability, non-current | $ 3,936,858 | $ 3,972,964 |
Right to Use Assets and Lease_5
Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Lessee Operating Lease Liability Maturity Abstract | ||
For the period ended December 31, 2023 | $ 945,102 | |
For the period ended December 31, 2024 | 884,990 | |
For the period ended December 31, 2025 | 906,666 | |
For the period ended December 31, 2026 | 926,988 | |
For the period ended December 31, 2027 | 946,745 | |
Thereafter | 1,939,476 | |
Total | 6,549,967 | |
Less: Present value discount | (2,170,243) | |
Lease liability | $ 4,379,724 | $ 4,134,802 |
SBA Loan Payable (Details)
SBA Loan Payable (Details) - PPP Loan [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | May 04, 2020 | |
SBA Loan Payable (Details) [Line Items] | ||
Debt Instrument, Face Amount | $ 460,400 | |
Debt Instrument, Interest Rate, Effective Percentage | 1% | |
Debt Instrument, Increase, Accrued Interest | $ 4,632 | |
Notes Payable | $ 460,406 |
Notes Payable (Details)
Notes Payable (Details) - USD ($) | 12 Months Ended | ||||||||||||||||||||||||||||||||||||
Dec. 02, 2022 | Nov. 29, 2022 | Oct. 24, 2022 | Oct. 10, 2022 | Oct. 07, 2022 | Sep. 15, 2022 | Sep. 14, 2022 | Sep. 02, 2022 | Aug. 18, 2022 | Aug. 04, 2022 | Jul. 27, 2022 | Jul. 26, 2022 | Jul. 21, 2022 | Jul. 07, 2022 | Jun. 09, 2022 | May 26, 2022 | May 23, 2022 | May 18, 2022 | May 10, 2022 | Apr. 27, 2022 | Apr. 26, 2022 | Apr. 18, 2022 | Apr. 06, 2022 | Mar. 18, 2022 | Feb. 24, 2022 | Dec. 30, 2021 | Jun. 23, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Nov. 18, 2022 | Oct. 05, 2022 | Jun. 22, 2022 | Jan. 12, 2022 | Nov. 10, 2021 | Oct. 18, 2021 | Mar. 25, 2021 | Dec. 31, 2020 | |
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 12,759 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 672,334 | 596,400 | |||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 4,630,372 | 4,266,669 | |||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 46,305 | $ 42,667 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 32,040 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 2,116,194 | 756,795 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | 40,000 | 0 | |||||||||||||||||||||||||||||||||||
Debt, Current | 5,112,702 | 0 | |||||||||||||||||||||||||||||||||||
Interest and Debt Expense | 3,210,763 | 968,471 | |||||||||||||||||||||||||||||||||||
Interest Expense, Debt | $ 362,094 | $ 7,657 | |||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||
Related Party [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Interest and Debt Expense | $ 1,243,639 | $ 0 | |||||||||||||||||||||||||||||||||||
Interest Expense, Debt | 198,753 | $ 0 | |||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.5 | ||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | $ 25 | |||||||||||||||||||||||||||||||||||
AJB Capital Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 750,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 15,000 | ||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 106,608 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 91,328 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 9,007 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | 675,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 349,914 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Expiration or Due Date | Mar. 17, 2023 | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate During Period | 10% | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 12% | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 62,000 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 424,914 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 750,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 22,833 | ||||||||||||||||||||||||||||||||||||
AJB Capital Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
AJB Capital Note [Member] | Commitments [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other | $ 430,000 | ||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 34,400 | ||||||||||||||||||||||||||||||||||||
AJB Capital Note [Member] | Original Issue Discount [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 75,000 | ||||||||||||||||||||||||||||||||||||
Anson Investments Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other | $ 322,500 | ||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 25,800 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 562,500 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 11,250 | ||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 27,040 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | 506,250 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 416,375 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Expiration or Due Date | Oct. 06, 2022 | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate During Period | 10% | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 12% | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 68,844 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 472,625 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 562,500 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 41,500 | ||||||||||||||||||||||||||||||||||||
Anson Investments Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Anson Investments Note [Member] | Original Issue Discount [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 56,250 | ||||||||||||||||||||||||||||||||||||
Anson East Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other | $ 107,500 | ||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 8,600 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 187,500 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 3,750 | ||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 9,014 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | 168,750 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 147,290 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Expiration or Due Date | Oct. 06, 2022 | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate During Period | 10% | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 12% | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 22,948 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 166,040 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 187,500 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 13,833 | ||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||
Anson East Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Anson East Note [Member] | Original Issue Discount [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 18,750 | ||||||||||||||||||||||||||||||||||||
GS Capital Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other | $ 159,259 | ||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 12,741 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 277,777 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 5,556 | ||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 21,920 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | 250,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 162,158 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Expiration or Due Date | Nov. 10, 2022 | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate During Period | 10% | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 12% | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 32,155 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 212,435 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 277,777 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 19,578 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount, Current | $ 27,777 | ||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | 10.45 | ||||||||||||||||||||||||||||||||||||
GS Capital Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Kishon Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other | $ 159,259 | ||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 12,741 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 277,777 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 5,556 | ||||||||||||||||||||||||||||||||||||
Derivative Liability | $ 27,793 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | 250,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 138,492 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Expiration or Due Date | Nov. 10, 2022 | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate During Period | 10% | ||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 12% | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 28,624 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 181,269 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 277,777 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 17,822 | ||||||||||||||||||||||||||||||||||||
Debt, Current | $ 277,777 | ||||||||||||||||||||||||||||||||||||
Kishon Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Kishon Note [Member] | Original Issue Discount [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 27,777 | ||||||||||||||||||||||||||||||||||||
Finnegan Note 1 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 47,059 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 386 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,930 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 3,240 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 40,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 3,285 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 17,005 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 51,765 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,285 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 20, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 2,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||
Finnegan Note 1 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
M Diamond Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 58,823 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 4,050 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 3,929 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 21,256 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 64,705 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,929 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 2,500 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
M Diamond Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Finnegan Note 2 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 29,412 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 242 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 242 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,025 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 25,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,965 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 10,625 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 32,353 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,965 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,250 | ||||||||||||||||||||||||||||||||||||
Finnegan Note 2 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Dragon Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 588,235 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 4,824 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 4,824 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 44,000 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 500,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 35,874 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 260,059 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 647,059 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 35,874 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 09, 2022 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 21,500 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Debt Issuance Costs, Gross | $ 47,500 | ||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||
Dragon Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Mackay Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 294,118 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 2,412 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 2,412 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 44,118 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 250,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 20,193 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 96,280 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 323,530 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 20,193 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Aug. 10, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 10,250 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||
Mackay Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Schrier Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 23,259 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 193 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 193 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,000 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 20,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,141 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 7,367 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 335 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 25,882 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,141 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Jan. 08, 2023 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 820 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Schrier Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Nommsen Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 58,823 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,350 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 2,946 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 18,905 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 64,705 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,946 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,850 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Nommsen Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Caplan Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 58,823 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,350 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 2,531 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 16,675 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 2,230 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 64,705 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,531 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Jan. 21, 2023 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,850 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Caplan Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Finnegan Note 3 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 29,412 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 242 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 242 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,100 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 25,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,200 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 7,575 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 1,728 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 32,353 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,200 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Feb. 03, 2023 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 850 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Finnegan Note 3 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Enright Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 984 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 120,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 984 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 6,317 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 102,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 4,899 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 29,571 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 6,746 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 132,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 4,899 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Feb. 03, 2023 | ||||||||||||||||||||||||||||||||||||
Enright Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Mitchell Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 71,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 582 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 3,124 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 60,350 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 2,817 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 20,874 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 78,100 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,817 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Mitchell Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Lightmas Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 60,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 492 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,640 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 51,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 2,380 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 17,640 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 66,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,380 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Lightmas Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Lewis Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 246 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,320 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 25,500 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,190 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 8,820 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 33,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,190 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Lewis Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Goff Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 246 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,320 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 25,500 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,190 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 8,820 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 33,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,190 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Goff Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Hagan Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 100,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 820 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 4,715 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 85,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 3,556 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 29,715 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 110,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,556 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 10, 2022 | ||||||||||||||||||||||||||||||||||||
Hagan Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Darling Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 200,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,640 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 10,824 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 170,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 6,619 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 60,824 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 220,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 6,619 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 15, 2022 | ||||||||||||||||||||||||||||||||||||
Darling Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Leath Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 410 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,868 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 42,500 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,641 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 15,368 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 55,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,641 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 15, 2022 | ||||||||||||||||||||||||||||||||||||
Debt Securities, Held-to-Maturity, Fair Value | $ 55,000 | ||||||||||||||||||||||||||||||||||||
Leath Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Cavalry Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 500,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 750 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 7,500 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 10,500 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 500,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 11,918 | ||||||||||||||||||||||||||||||||||||
Cavalry Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Cavalry Note [Member] | Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 1,000,000 | ||||||||||||||||||||||||||||||||||||
Cavalry Note [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 750,000 | ||||||||||||||||||||||||||||||||||||
Cavalry Exchange Agreement [Member] | Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 1,000,000 | ||||||||||||||||||||||||||||||||||||
Cavalry Exchange Agreement [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 750,000 | ||||||||||||||||||||||||||||||||||||
Mercer Note 1 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 300,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 750 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | $ 6,986 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 10,500 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 300,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 6,986 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||
Mercer Note 1 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Mercer Note 1 [Member] | Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 47,619 | ||||||||||||||||||||||||||||||||||||
Mercer Note 1 [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 750,000 | ||||||||||||||||||||||||||||||||||||
Mercer Exchange Agreement [Member] | Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 47,619 | ||||||||||||||||||||||||||||||||||||
Mercer Exchange Agreement [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 750,000 | ||||||||||||||||||||||||||||||||||||
Pinz Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 30,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | $ 6,986 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 2,100 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 30,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 674 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||
Pinz Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Pinz Note [Member] | Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 100,000 | ||||||||||||||||||||||||||||||||||||
Pinz Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Shares Issuable (in Shares) | 100,000 | ||||||||||||||||||||||||||||||||||||
Mercer Note 2 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 100,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | $ 1,863 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 1,900 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 100,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,863 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 31, 2022 | ||||||||||||||||||||||||||||||||||||
Mercer Note 2 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Mercer Note 3 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 125,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 750 | 750 | |||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 4,028 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 20,972 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 125,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 993 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | May 21, 2023 | ||||||||||||||||||||||||||||||||||||
Mercer Note 3 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Howe Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,000,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 42,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 42,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 261,568 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 850,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 106,795 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 511,568 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 1,100,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 106,795 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 37.5 | ||||||||||||||||||||||||||||||||||||
Howe Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Diamond Note 1 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 175,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 7,350 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 7,350 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,914 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 148,750 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 16,052 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 46,664 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 192,500 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 16,052 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 37.5 | ||||||||||||||||||||||||||||||||||||
Diamond Note 1 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Diamond Note 2 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 235,294 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 1,930 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 200,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,676 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 61,036 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 23,529 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,676 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 2,213 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Repaid, Principal | 235,294 | ||||||||||||||||||||||||||||||||||||
Diamond Note 2 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Diamond Note 3 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other | $ 16,200 | ||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 1,929 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 235,294 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 1,930 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,930 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 16,200 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 200,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 17,586 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 83,823 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 258,823 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 17,586 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 8,800 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||
Diamond Note 3 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Diamond Note 4 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 47,059 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 386 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,930 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 3,160 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 40,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 3,245 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 17,885 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 51,765 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,245 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 2,960 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||
Diamond Note 4 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Diamond Note 5 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 58,823 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 483 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 4,050 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 3,929 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 21,256 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 64,705 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,929 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 2,500 | ||||||||||||||||||||||||||||||||||||
Diamond Note 5 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Lindstrom Note 1 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 41,176 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 338 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 338 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 2,835 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 35,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 2,750 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 14,879 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 45,294 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,750 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,750 | ||||||||||||||||||||||||||||||||||||
Lindstrom Note 1 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Dobbertin Note 1 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 17,647 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 145 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 145 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,215 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 15,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,179 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 6,377 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 19,412 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,179 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 750 | ||||||||||||||||||||||||||||||||||||
Dobbertin Note 1 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Howe Note 2 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 300,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 2,460 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 2,460 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 22,440 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 255,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 18,888 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 108,405 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 330,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 18,888 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 10,965 | ||||||||||||||||||||||||||||||||||||
Howe Note 2 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Howe Note 3 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 300,000 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 2,460 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 2,460 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 12,495 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 255,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 15,436 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 97,440 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 330,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 15,436 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 9,945 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Howe Note 3 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Iturregui Note [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 241 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 29,412 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 242 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 242 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,225 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 25,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 1,313 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 8,464 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 1,089 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 32,353 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 1,313 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Jan. 21, 2023 | ||||||||||||||||||||||||||||||||||||
Share Price (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding | $ 975 | ||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||
Iturregui Note [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
Howe Note 4 [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 200,000 | ||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 1,640 | ||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 10,775 | ||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale | $ 170,000 | ||||||||||||||||||||||||||||||||||||
Interest Expense, Long-Term Debt | 8,756 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 60,775 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 0 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 220,000 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 8,756 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||
Howe Note 4 [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% | ||||||||||||||||||||||||||||||||||||
November 29, 2022 Notes [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding (in Shares) | 750 | ||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 667 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Discount Outstanding | 3,083 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | 18,750 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 164 | ||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | May 28, 2023 | ||||||||||||||||||||||||||||||||||||
November 29, 2022 Notes [Member] | Measurement Input, Default Rate [Member] | |||||||||||||||||||||||||||||||||||||
Notes Payable (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 18% |
Notes Payable (Details) - Sche
Notes Payable (Details) - Schedule of Debt - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Schedule Of Debt Abstract | ||
Notes Payable | $ 5,144,742 | $ 0 |
Less: Discount | (32,040) | |
Notes payable - net of discount | 5,112,702 | 0 |
Current Portion, net of discount | 5,112,702 | 0 |
Long-term portion, net of discount | $ 0 | $ 0 |
Notes Payable - Related Parties
Notes Payable - Related Parties (Details) - Schedule of Debt, Related Parties - Related Party [Member] - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Notes Payable - Related Parties (Details) - Schedule of Debt, Related Parties [Line Items] | ||
Notes Payable | $ 2,799,632 | $ 1,100,000 |
Less: Discount | (22,670) | (511,568) |
Notes payable – net of discounts | 2,776,962 | 588,432 |
Current Portion, net of discount | 2,776,962 | 588,432 |
Long-term portion, net of discount | $ 0 | $ 0 |
Derivative Liabilities (Details
Derivative Liabilities (Details) - Schedule of Derivative Liability Acitivity - USD ($) | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Schedule Of Derivative Liability Acitivity Abstract | ||
Balance | $ 0 | $ 807,683 |
True-up features issued | 192,375 | |
Settled upon conversion or exercise | (310,641) | (1,302,138) |
Loss on revaluation | 687,178 | 494,455 |
Balance | $ 568,912 | $ 0 |
Derivative Liabilities (Detai_2
Derivative Liabilities (Details) - Schedule of Valuation Assumptions | 12 Months Ended |
Dec. 31, 2022 $ / shares | |
Minimum [Member] | |
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items] | |
Volatility | 95.10% |
Stock Price (in Dollars per share) | $ 1.06 |
Risk-free interest rates | 4.35% |
Term (years) | 8 months 23 days |
Maximum [Member] | |
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items] | |
Volatility | 123.20% |
Stock Price (in Dollars per share) | $ 3.5 |
Risk-free interest rates | 4.37% |
Term (years) | 10 months 9 days |
Stockholders_ Equity (Deficit_2
Stockholders’ Equity (Deficit) (Details) - USD ($) | 1 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nov. 18, 2022 | Nov. 07, 2022 | Oct. 01, 2022 | Sep. 15, 2022 | Sep. 14, 2022 | Sep. 09, 2022 | Sep. 02, 2022 | Aug. 18, 2022 | Aug. 04, 2022 | Jul. 27, 2022 | Jul. 26, 2022 | Jul. 21, 2022 | Jul. 07, 2022 | Jun. 22, 2022 | Jun. 09, 2022 | Jun. 07, 2022 | May 26, 2022 | May 23, 2022 | May 18, 2022 | May 10, 2022 | May 01, 2022 | Apr. 27, 2022 | Apr. 18, 2022 | Apr. 06, 2022 | Mar. 31, 2022 | Mar. 31, 2022 | Mar. 18, 2022 | Jan. 12, 2022 | Jan. 05, 2022 | Nov. 10, 2021 | Oct. 18, 2021 | Aug. 17, 2021 | Jun. 23, 2021 | May 12, 2021 | Apr. 19, 2021 | Mar. 25, 2021 | Mar. 23, 2021 | Mar. 17, 2021 | Mar. 11, 2021 | Feb. 22, 2021 | Feb. 05, 2021 | Feb. 01, 2021 | Jan. 28, 2021 | Jan. 21, 2021 | Jan. 14, 2021 | Jan. 11, 2021 | Jan. 06, 2021 | Jan. 04, 2021 | Sep. 02, 2021 | Jun. 29, 2021 | May 26, 2021 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Oct. 18, 2022 | Oct. 10, 2022 | Oct. 07, 2022 | Oct. 05, 2022 | Dec. 31, 2020 | |
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 4,630,372 | 4,266,669 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Outstanding | 4,630,372 | 4,266,669 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Salaries, Current (in Dollars) | $ 19,032 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited | 8,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited (in Dollars) | $ 80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gains (Losses) on Restructuring of Debt (in Dollars) | $ 15,032 | $ 15,032 | $ 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities, Current (in Dollars) | 507 | 19,205 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 12,759 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 10 | $ 15 | $ 15 | $ 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | 198,273 | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 32,040 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 75,934 | 596,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 672,334 | 596,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services | 12,064 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Issued for Services (in Dollars) | $ 77,448 | $ 101,250 | $ 222,480 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $ 180,573 | $ 252,029 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | 50,000 | 6,720 | 102,333 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 9,589 | 84,748 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 12,515 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Repurchased and Retired During Period, Shares | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued Liabilities, Current (in Dollars) | $ 156,441 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares Subscribed but Unissued | 2,926 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 6,256 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock, Value, Shares Issued Net of Tax Withholdings (in Dollars) | $ 78,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period | 13,032 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 100,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends, Preferred Stock (in Dollars) | $ 322,310 | $ 185,204 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | 0 | 51,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Value, Issued (in Dollars) | $ 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Before Reverse-Split [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Outstanding | 231,374,330 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
After Reverse-Split [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Outstanding | 4,630,372 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Reverse Stock Splits | 226,743,958 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Subscribed [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 7,648 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 12.5 | $ 12.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $ 252,029 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AJB Capital Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 349,914 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 675,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounts Payable [Member] | Stock Subscribed [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 95,558 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cavalry Fund 1 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 14,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued (in Dollars) | $ 91,440 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised (in Dollars) | $ 88,560 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diamond Note 3 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 1,929 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 8 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 765 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract Shares, Value (in Dollars) | $ 24,118 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | 15,434 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other (in Dollars) | $ 16,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 1,929 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 235,294 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 1,930 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 8,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diamond Note 4 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 386 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 7.585 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 249 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 3,160 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 386 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 47,059 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 386 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 2,960 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finnegan Note 1 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 386 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 8.97 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 222 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 3,240 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 386 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 47,059 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 20, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 386 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
May 26 Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 1,688 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 7.585 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 1,369 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 14,175 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 1,688 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series X Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 8,103 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
June 9 Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 7,284 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 7,425 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 9,356 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 66,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 7,284 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dragon Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 4,824 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 588,235 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 09, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 4,824 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 21,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Fee, Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GS Capital Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 12,741 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 12,741 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 162,158 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other (in Dollars) | 159,259 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 277,777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 5,556 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Fee, Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anson East Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 8,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 8,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 147,290 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other (in Dollars) | 107,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 187,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 3,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 168,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anson Investments Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 25,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 25,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 416,375 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Other (in Dollars) | 322,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 562,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 11,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 506,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Fee, Per Share (in Dollars per share) | $ 10.45 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mackay Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 5,456 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 12,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 2,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 294,118 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Aug. 10, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 2,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 10,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Fee, Per Share (in Dollars per share) | $ 7.445 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schrier Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 193 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 7.445 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 436 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 193 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 23,259 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Jan. 08, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 193 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 820 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Iturregui Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 241 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 7.225 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 518 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 1,225 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 241 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 29,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Jan. 21, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 242 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 975 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Howe Note 3 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,460 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 7.225 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 5,729 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 12,495 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 2,460 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 2,460 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 9,945 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 255,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nommsen Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 482 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 949 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 2,350 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 482 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 58,823 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 483 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 1,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Caplan Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 482 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.935 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 995 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 2,350 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 482 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 58,823 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Jan. 21, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 483 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 1,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Finnegan Note 3 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 241 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 448 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 241 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 29,412 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Feb. 03, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 242 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Enright Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 984 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 6,317 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Feb. 03, 2023 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 102,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Howe Note 4 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,640 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 10,775 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 170,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mitchell Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 582 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 5.365 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 3,124 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 71,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 60,350 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lightmas Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 492 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 5.365 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 2,640 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 51,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lewis Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 246 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 5.365 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 1,320 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 25,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Goff Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 246 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 5.65 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 1,320 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 30, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 25,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hagan Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 820 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 5.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 4,715 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 10, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 85,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Darling Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,640 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 10,824 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 15, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 170,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leath Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 410 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.995 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitment Shares, Value (in Dollars) | $ 2,868 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Dec. 15, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 42,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 4 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.612 | $ 0.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 70,119 | 82,475 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 4 [Member] | Principal [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 39,000 | $ 45,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 4 [Member] | Accrued Interest [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 3,913 | $ 4,485 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 5 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.633 | $ 0.612 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 86,388 | 89,270 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 5 [Member] | Principal [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 50,000 | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 5 [Member] | Accrued Interest [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 4,683 | $ 4,633 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 6 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.7875 | $ 0.77 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 145,702 | 128,992 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 6 [Member] | Principal [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 107,200 | $ 93,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 6 [Member] | Accrued Interest [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 7,540 | $ 6,324 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 133,440 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $ 1,668,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 7 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 12.492 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 23,683 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 200,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 8 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 11.926 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 12,792 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 114,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 9 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 12,492 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 12,104 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 114,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Equities Note 10 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 11,874 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 21,903 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount (in Dollars) | $ 200,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Good Clinic [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 12,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Service Provider [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 15.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services | 6,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Underwriters of the 2021 Private Placement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 9,227 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 13 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Professional Fees [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Issued for Services | 39 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 12% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends, Preferred Stock (in Dollars) | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Value, Issued (in Dollars) | $ 0 | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | The Good Clinic [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited | 4,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 4,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.25 | $ 12.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 80,000 | 4,237,424 | 98,064 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Shares Converted | 1,000,000 | 1,059,356 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 1,038,708 | 940,644 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends, Preferred Stock (in Dollars) | $ 66,447 | $ 87,059 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | Voting Rights. Holders of the Series C Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Terms | Conversion. Each holder of our Series C Preferred Stock is entitled to convert their shares of Series C Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series C Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series C Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in Dollars per share) | $ 0.25 | $ 0.25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Payment Terms | Dividends. Each share of Series C Preferred Stock accrues dividends on a quarterly basis in arrears, at the rate of 6% per annum of the Stated Value ($1.05 per share plus any accrued but unpaid dividends) and is to be paid within 15 days after the end of each of our fiscal quarters. Each holder of the Series C Preferred Stock is entitled to receive dividends or distributions on each share of the Series C Preferred Stock on an as converted into Common Stock basis when and if dividends are declared on the Common Stock by our Board of Directors. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Redemption Terms | Redemption Rights. Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series C Preferred Stock (which the applicable holder of the Series C Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series C Preferred Stock that the Series C Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series C Preferred Stock specified in such request by paying in cash therefore a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Preemptive Rights | Preemptive or Similar Rights Additionally, except for a public offering or certain exempt issuances of our securities, holders of the Series C Preferred Stock shall have the right to participate in any offering of our Common Stock or Common Stock Equivalents (as defined in the COD) in a transaction exempt from registration under the Securities Act in an amount equal to an aggregate of 30% of the financing on the same terms, conditions and price provided to investors in such an offering, such right shall expire on the 15 month anniversary of the issuance date of the Series C Preferred Stock. Further, until the earlier of 18 months from the issuance date of the Series C Preferred Stock and the date that there are less than 20% of the shares of Series C Preferred Stock outstanding, the Investors have most favored nations protection in the event we issue or sell Common Stock or Common Stock Equivalents that the Investors believe are more favorable than the terms and conditions under the Private Placement. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion of Stock, Amount Issued (in Dollars) | $ 981 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 6,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 5 years | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | $ 3,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion | 4,000,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues (in Dollars) | $ 1,491,283 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 1,038,708 | 940,644 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Value, Issued (in Dollars) | $ 10,476 | $ 9,406 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | Warrants 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 6,300,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | Cavalry Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | Mercer Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 47,619 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,075,000 | 2,050,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 25 | $ 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 6% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 3,100,000 | 3,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends, Preferred Stock (in Dollars) | $ 195,299 | $ 35,327 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | Voting Rights. Holders of the Series D Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Terms | Conversion. Each holder of our Series D Preferred Stock is entitled to convert their shares of Series D Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series D Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series D Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in Dollars per share) | $ 0.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Payment Terms | Dividends. Each share of Series D Preferred Stock accrues dividends on a quarterly basis in arrears, at the rate of 6% per annum of the Stated Value ($1.05 per share plus any accrued but unpaid dividends) and is to be paid within 15 days after the end of each of our fiscal quarters. Each holder of the Series C Preferred Stock is entitled to receive dividends or distributions on each share of the Series D Preferred Stock on an as converted into Common Stock basis when and if dividends are declared on the Common Stock by our Board of Directors. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Redemption Terms | Redemption Rights. Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series D Preferred Stock (which the applicable holder of the Series D Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series D Preferred Stock that the Series D Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series D Preferred Stock specified in such request by paying in cash therefore a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Preemptive Rights | Preemptive or Similar Rights Additionally, except for a public offering or certain exempt issuances of our securities, holders of the Series D Preferred Stock shall have the right to participate in any offering of our Common Stock or Common Stock Equivalents (as defined in the COD) in a transaction exempt from registration under the Securities Act in an amount equal to an aggregate of 30% of the financing on the same terms, conditions and price provided to investors in such an offering, such right shall expire on the 15 month anniversary of the issuance date of the Series D Preferred Stock. Further, until the earlier of 18 months from the issuance date of the Series D Preferred Stock and the date that there are less than 20% of the shares of Series D Preferred Stock outstanding, the Investors have most favored nations protection in the event we issue or sell Common Stock or Common Stock equivalents that the Investors believe are more favorable than the terms and conditions under the Private Placement. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 45,150 | 85,050 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 5 years | 5 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | $ 999,250 | $ 1,874,450 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Issuance Costs, Net (in Dollars) | $ 75,750 | $ 125,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues (in Dollars) | $ 1,753,282 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 3,100,000 | 3,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Value, Issued (in Dollars) | $ 31,000 | $ 31,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | Warrants 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Rights, Granted | 45,150 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 37.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Preemptive Rights | $37.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 85,050 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | Cavalry Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | Mercer Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | Pinz Exchange Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | Anson East and Anson Investments Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars) | $ 1,100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Convertible, Conversion Price (in Dollars per share) | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues (in Dollars) | $ 1,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Series X Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Authorized | 27,324 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | $ 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding | 24,227 | 24,227 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends, Preferred Stock (in Dollars) | $ 60,564 | $ 61,818 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Dividend Payment Terms | The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Shares Issued | 24,227 | 24,227 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Value, Issued (in Dollars) | $ 242 | $ 242 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valuation, Market Approach [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Valuation, Market Approach [Member] | Enright Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Uplisting Offering [Member] | Anson East and Anson Investments Notes [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred Stock, Value, Issued (in Dollars) | $ 375,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Waiver Fee [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 30,835 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 12.5 | $ 12.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Noncash Expense (in Dollars) | $ 385,431 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(in Dollars) | $ 198,273 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement, Option [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars) | $ 2,152,786 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gardner Agreement [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Amount (in Dollars) | $ 500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Accrued Liabilities, Current (in Dollars) | $ 294,912 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gardner Agreement [Member] | Restricted Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 63,593 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AJB Capital Investors [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 91,328 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Other | 34,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contract, Price per share (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjustments to Additional Paid in Capital, Other (in Dollars) | $ 226,106 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AJB Capital Investors [Member] | Valuation, Market Approach [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 6.35 | $ 6.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AJB Capital Investors [Member] | Warrant and Commitment Fees [Member] | AJB Capital Note [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 349,914 | $ 349,914 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Service Provider [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 16 | $ 6.88 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 6,329 | 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kishon Investments SPA [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 12,741 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (in Dollars) | $ 27,777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 12.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount (in Dollars) | $ 159,259 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount (in Dollars) | $ 277,777 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Maturity Date | Nov. 10, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 5,556 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrants and Rights Outstanding (in Dollars) | $ 159,259 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars) | $ 250,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Officers and Board Members [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders’ Equity (Deficit) (Details) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value (in Dollars) | $ 676,423 |
Stockholders_ Equity (Deficit_3
Stockholders’ Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - $ / shares | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Share Based Payment Arrangement Option Exercise Price Range Abstract | |||
Range of exercise prices | $ 1.5 | ||
Range of exercise prices | $ 16 | ||
Number of options outstanding (in Shares) | 310,692 | 366,591 | 269,078 |
Weighted average remaining contractual life (years) | 7 years 11 months 19 days | ||
Weighted average exercise price of outstanding options | $ 10.01 | $ 10.29 | $ 1.5 |
Number of options exercisable (in Shares) | 136,303 | ||
Weighted average exercise price of exercisable options | $ 7.89 |
Stockholders_ Equity (Deficit_4
Stockholders’ Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Activity - $ / shares | 1 Months Ended | 12 Months Ended | |||
May 12, 2021 | Feb. 22, 2021 | Jun. 29, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
Share Based Payment Arrangement Option Activity Abstract | |||||
Outstanding, Number of Shares | 366,591 | 269,078 | |||
Outstanding, Weighted-Average Exercise Price | $ 10.29 | $ 1.5 | |||
Options Vested and Exercisable, Number of Shares | 136,303 | ||||
Options Vested and Exercisable, Weighted-Average Exercise Price | $ 7.89 | ||||
Granted, Number of Shares | 4,000 | 285,900 | |||
Granted, Weighted-Average Exercise Price | $ 12.5 | $ 13 | |||
Cancelled/Expired, Number of Shares | (59,899) | (7,000) | |||
Cancelled/Expired, Weighted-Average Exercise Price | $ 12.18 | $ 1.5 | |||
Exercised, Number of Shares | 50,000 | 6,720 | 102,333 | 0 | |
Exercised, Weighted-Average Exercise Price | $ 0 | ||||
Outstanding, Number of Shares | 310,692 | 366,591 | |||
Outstanding, Weighted-Average Exercise Price | $ 10.01 | $ 10.29 |
Stockholders_ Equity (Deficit_5
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - Share-Based Payment Arrangement, Option [Member] | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items] | ||
Dividends | 0% | 0% |
Term (years) | 5 years | |
Minimum [Member] | ||
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items] | ||
Volatility | 134.90% | 153.50% |
Risk-free interest rates | 2.82% | 0.82% |
Term (years) | 5 years | |
Maximum [Member] | ||
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items] | ||
Volatility | 149.90% | 183.50% |
Risk-free interest rates | 4.25% | 1.69% |
Term (years) | 6 years 6 months |
Stockholders_ Equity (Deficit_6
Stockholders’ Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares | 12 Months Ended | |
Dec. 31, 2022 | Dec. 31, 2021 | |
Schedule Of Stockholders Equity Note Warrants Or Rights Abstract | ||
Outstanding, Number of Shares | 596,400 | |
Outstanding, Weighted Average Exercise Price | $ 31.25 | |
Granted, Number of Shares | 75,934 | 596,400 |
Granted, Weighted Average Exercise Price | $ 26.21 | $ 31.25 |
Exercised, Number of Shares | 0 | 0 |
Exercised, Weighted Average Exercise Price | $ 0 | $ 0 |
Outstanding, Number of Shares | 672,334 | 596,400 |
Outstanding, Weighted Average Exercise Price | $ 30.68 | $ 31.25 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Income Tax Disclosure [Abstract] | ||
Deferred Tax Assets, Operating Loss Carryforwards | $ 9,679,000 | $ 8,478,000 |
Income Taxes (Details) - Schedu
Income Taxes (Details) - Schedule of Components of Income Tax Expense - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Schedule Of Components Of Income Tax Expense Abstract | |||
Current | $ 0 | $ 0 | |
Deferred | 0 | 0 | |
Total | $ 0 | $ 0 | $ 0 |
Income Taxes (Details) - Sche_2
Income Taxes (Details) - Schedule of Income Tax Rate Reconciliation - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Schedule Of Income Tax Rate Reconciliation Abstract | |||
Expected tax at statutory rates | $ (4,879,000) | $ (2,351,000) | |
Expected tax at statutory rates | 21% | 21% | |
Permanent Differences | $ 1,610,000 | $ 692,000 | |
Permanent Differences | 7% | 6% | |
State Income Tax, Net of Federal benefit | $ 380,000 | $ (612,000) | |
State Income Tax, Net of Federal benefit | 2% | 5% | |
Current Year Change in Valuation Allowance | $ 2,137,000 | $ 2,291,000 | |
Current Year Change in Valuation Allowance | 9% | 20% | |
Prior Year True-Ups | $ 752,000 | $ (20,000) | |
Prior Year True-Ups | 3% | 0% | |
Income tax expense | $ 0 | $ 0 | $ 0 |
Income tax expense | 0% | 0% |
Income Taxes (Details) - Sche_3
Income Taxes (Details) - Schedule of Deferred Income Taxes - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Schedule Of Deferred Income Taxes Abstract | ||
Accrued payroll | $ 112,000 | $ 22,000 |
ASC842-ROU Asset | (68,000) | (1,117,000) |
ASC842-ROU (Liability) | 830,000 | 1,189,000 |
Gain from derivatives | (130,000) | (4,000) |
Waiver and commitment fee shares | (32,000) | |
Stock based compensation | (85,000) | 398,000 |
Depreciation | 33,000 | (764,000) |
Net operating loss | 9,679,000 | 8,478,000 |
Net deferred tax assets (liabilities) | 10,339,000 | 8,202,000 |
Valuation allowance | (10,339,000) | (8,202,000) |
Net deferred tax assets (liabilities) | $ 0 | $ 0 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items] | ||
Derivative liabilities | $ 568,912 | $ 0 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items] | ||
Derivative liabilities | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ||
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items] | ||
Derivative liabilities | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items] | ||
Derivative liabilities | $ 568,912 | $ 0 |
Commitments and Contingencies (
Commitments and Contingencies (Details) - USD ($) | Oct. 25, 2022 | Dec. 31, 2022 | Jul. 21, 2020 | May 04, 2020 |
Commitments and Contingencies (Details) [Line Items] | ||||
Debt Instrument, Interest Rate, Effective Percentage | 1% | |||
Lease Termination Commitment Due | $ 25,000 | |||
Paid to Plaintiff [Member] | ||||
Commitments and Contingencies (Details) [Line Items] | ||||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares (in Shares) | 2,552 | |||
Paid to CEO [Member] | ||||
Commitments and Contingencies (Details) [Line Items] | ||||
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares (in Shares) | 19,622 | |||
Payments for Legal Settlements | $ 3,000 | |||
PPP Loan [Member] | ||||
Commitments and Contingencies (Details) [Line Items] | ||||
Loan Proceeds Erroneously Given | $ 440,000 | |||
Debt Instrument, Interest Rate, Effective Percentage | 1% |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) | 12 Months Ended | |||||||||||||||||||
Jun. 01, 2023 | Apr. 11, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | May 09, 2023 | May 05, 2023 | Apr. 04, 2023 | Mar. 28, 2023 | Mar. 23, 2023 | Mar. 09, 2023 | Mar. 01, 2023 | Feb. 21, 2023 | Feb. 15, 2023 | Jan. 23, 2023 | Jan. 12, 2023 | Nov. 07, 2022 | Jun. 29, 2021 | Jun. 23, 2021 | May 12, 2021 | Feb. 22, 2021 | |
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Shares, Issued | 4,630,372 | 4,266,669 | ||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 15 | $ 10 | $ 15 | $ 15 | ||||||||||||||||
Preferred Stock, Shares Authorized | 100,000,000 | |||||||||||||||||||
Proceeds from Issuance of Debt (in Dollars) | $ 4,359,350 | $ 0 | ||||||||||||||||||
Sheila Schweitzer [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Salary and Wage, Officer, Excluding Cost of Good and Service Sold (in Dollars) | $ 200,000 | |||||||||||||||||||
Series E Preferred Stock [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Preferred Stock, Shares Authorized | 10,000 | |||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | |||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Shares, Issued | 19,622 | 2,552 | 94,738 | 18,472 | 15,265 | 13,555 | 150,000 | 9,846 | 8,063 | |||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.94 | $ 1.05 | $ 1.32 | $ 1.32 | $ 1.32 | $ 1.32 | $ 2.63 | $ 1.32 | $ 4.33 | |||||||||||
Proceeds from Issuance of Debt (in Dollars) | $ 650,000 | |||||||||||||||||||
Proceeds from Debt, Net of Issuance Costs (in Dollars) | $ 511,000 | |||||||||||||||||||
Subsequent Event [Member] | Series F Preferred Stock [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Preferred Stock, Shares Authorized | 140,000 | |||||||||||||||||||
Preferred Stock, Value, Outstanding (in Dollars) | $ 1,000 | |||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | |||||||||||||||||||
Subsequent Event [Member] | Series E Preferred Stock [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.01 | |||||||||||||||||||
Service Provider [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Shares, Issued | 2,952 | 150,000 | ||||||||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 1.05 | $ 3.45 | ||||||||||||||||||
Larry Diamond [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Shares, Issued | 666 | |||||||||||||||||||
Spartan Capital [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Shares, Issued | 150,000 | |||||||||||||||||||
Spartan Capital [Member] | Subsequent Event [Member] | After Completion of Gross Raise [Member] | ||||||||||||||||||||
Subsequent Events (Details) [Line Items] | ||||||||||||||||||||
Common Stock, Shares, Issued | 50,000 |